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Rb-Raf-1 Interaction as a Therapeutic Target for Proliferative Disorders 
Rebecca Kinkade 
ABSTRACT 
  The retinoblastoma tumor suppressor protein, Rb, is a key regulator of the 
mammalian cell cycle and its inactivation facilitates S-phase entry. Rb is 
inactivated through multiple waves of phosphorylation, mediated mainly by 
kinases associated with D and E type cyclins in the G1 phase of the cell cycle. 
Our earlier studies had shown that the signaling kinase Raf-1 (c-Raf) physically 
interacts with Rb upon growth factor stimulation and initiates the phosphorylation 
cascade. We had shown that an 8 amino acid peptide derived from Raf-1 could 
disrupt the Rb-Raf-1 interaction leading to an inhibition of Rb phosphorylation, 
cell proliferation and tumor growth in nude mice.  Here, we describe a newly 
identified orally-active small molecule, RRD-251 (Rb – Raf-1 Disruptor 251), that 
disrupts potently and selectively the binding of Raf-1 to Rb; it had no effect on 
Rb-HDAC1, Rb-Prohibitin, Rb-Ask1, Rb-cyclin E, or Raf-1-Mek interactions. 
RRD-251 inhibited anchorage-dependent and –independent growth of human 
cancer cells; it could also potently inhibit angiogenesis both in vitro and in vivo.  
Oral or intra-peritoneal administration of RRD-251 resulted in a significant 
suppression of growth of tumors xenotransplanted into athymic nude mice; the 
tumor suppressive effects were restricted to tumors carrying a wild-type Rb gene. 
 xiii 
Thus, selective targeting of Rb-Raf-1 interaction appears to be a promising 
approach for developing novel anti-cancer agents.  In addition to mitogens, 
tobacco components like NNK and nicotine can induce cell proliferation and 
angiogenesis, contributing to lung cancer. Induction of cell proliferation by 
tobacco components required the binding of Raf-1 to Rb and RRD-251 could 
prevent nicotine induced cell proliferation. Our studies also show how nicotine 
not only promotes tumor growth in vivo, it also increases chance of tumor 
recurrence and metastasis. In addition to growth factors and tobacco 
components, cytokines like TNF could induce Rb-Raf-1 interaction in vascular 
smooth muscle cells. Since TNF-induced proliferation of vascular smooth 
muscle cells contributes to growth of atherosclerotic plaques, RRD-251 could be 
beneficial in controlling atherosclerosis as well. Thus, it appears that drugs that 
can disrupt the Rb-Raf-1 interaction might have beneficial effects in a wide 
spectrum of human diseases.  
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Chapter 1: Introduction 
 
 
1.  The retinoblastoma tumor suppressor gene and cell cycle 
 
While the presence of tumor suppressor genes have been realized for 
many years, the retinoblastoma tumor suppressor gene (RB) was the first to be 
identified and cloned (1).  Recognized as the first identified tumor suppressor 
gene, RB was identified based on studies on the inheritance pattern of 
retinoblastoma, which is a pediatric tumor of the eye. Retinoblastoma could be 
familial or sporadic; familial forms are bilateral and mutifocal while sporadic forms 
are unilateral (2). Based on these observations, Alfred Knudsen proposed that 
the retinoblastoma arises after two genetic events; this led to the “two-hit 
hypothesis” meaning that 2 independent “hits” (mutations) are required in the 
same cell to initiate cancer (2). Several laboratories cloned the RB tumor 
suppressor gene in the late 1980s through positional cloning of minimally deleted 
chromosomal regions (1,3,4). Rb protein was found to be a 928 amino acid 
nuclear phospho protein that has no catalytic activity and very weak DNA binding 
activity (3). It was found that viral oncoproteins such as SV40 large T antigen, 
adenovirus E1A and human papilloma virus E7 are capable of binding to Rb and 
disrupting its tumor suppressive function (5-7). Mutants of such viral oncoproteins 
that could not bind to Rb could not transform cells; further, mutant Rb proteins 
found in tumors could not bind to the viral oncoproteins (5,7). These findings led 
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to the hypothesis that binding of these viral oncoproteins caused an inactivation 
of the Rb protein equivalent to mutating its gene. This finding also revealed how 
viral oncoproteins can instigate tumor formation by inactivation of a tumor 
suppressor protein, Rb (5,7). 
 
1.1 Regulation of cell cycle by Rb 
   Further studies showed that that there are many cellular proteins that bind 
to Rb and this allowed Rb to regulate a variety of cellular processes (8). Such 
proteins can be classified into two groups – those that are upstream of Rb and 
regulate or affect Rb function and those that are downstream of Rb, facilitating 
Rb functions. The major downstream targets of Rb are those involved in 
transcriptional control; these include the E2F family of transcription factors (9). 
E2F family members bind to DNA as heterodimers with DP proteins, DP1 or DP2 
(Dimerization partner 1 or 2) (10). E2F-DP complexes bind to the canonical 
sequence TTTCGCGC or its derivatives present on many cellular promoters and 
regulate the expression of genes involved in DNA replication, cell cycle 
progression and DNA repair (11-15). 
In quiescent cell (G0) and early in G1, Rb remains hypo-phosphorylated 
and is in its active state; this is when Rb is most efficient at binding and 
repressing E2F regulated genes (16). Mutant Rb proteins that are unable to bind 
to E2F cannot inhibit transcription (17). In response to mitogenic stimulation, Rb 
becomes increasingly phosphorylated, causing Rb to become less efficient at 
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interacting with associated proteins such as E2F and co-repressor molecules 
(18).  Therefore, phosphorylation of Rb weakens its ability to repress 
transcription. The phosphorylation of Rb is catalyzed by cyclin/ cyclin dependent 
kinase (CDK) complexes (19-21).  
  The cyclin/CDK complexes that phosphorylate Rb in G1 phase are cyclin 
D/CDK4/6 and cyclin E/cdk2. Mitogenic signaling (growth factor stimulation) 
leads to activation of cyclin/CDK complexes. Cyclin/CDK complexes in G1 
efficiently phosphorylate Rb to completely inactivate its transcriptional repressor 
function, thus allowing expression of E2F target genes (22,23). E2F functions to 
activate genes that are essential for entry into S-phase (24,25). Rb remains 
inactive throughout the remainder of the cell cycle. Mitotic cyclins/CDK 
complexes CDK2/cyclin A and CDK1/cyclin B phosphorylate Rb and mediate the 
progression through the S/G2/M phases of the cell cycle (26). Rb 
phosphorylation is reversed by dephosphorylation, causing a transient 
reactivation. From anaphase to G1 protein phosphatase 1 (PP1) 
dephosphorylates Rb in response to growth inhibitory signals (27,28). Under 
normal conditions, it is assumed that PP1 complexes contain PP1 regulatory 
proteins termed PNUTs (29). During hypoxic conditions or in the presence of 
chemotherapeutics, PNUTS were found to dissociate from PP1 and this led to 
the activation of PP1 towards Rb, causing an early dephosphorylation of Rb (29). 
These findings support that inactive and active Rb serves as a critical controller 
of cell proliferation and growth suppression. 
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Figure 1. Cell cycle dependent regulation of Rb/E2F. Mitogenic signals stimulate 
the accumulation of cyclin dependent kinases and initiate phosphorylation of Rb 
in G1 phase of the cell cycle. Once Rb is inactivated though phosphorylation it 
releases E2F to induce S-phase genes. Late in mitosis, Rb is dephosphorylated 
by protein phosphatase 1 (PP1). 
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1.2 Rb family members  
  Rb belongs to a family of three proteins, generally referred to as the 
„pocket proteins‟; the family consists of Rb, p107 and p130 (30). They are termed 
pocket proteins because of a shared domain called the pocket through which 
these proteins bind viral oncoproteins, cellular proteins and transcription factors. 
RB and p130 are found on chromosomes 13q14 and 16p12.2, in which mutations 
are evident in cancer (31). The p107 gene has been mapped to chromosome 
20q11.2, which is not frequently mutated in cancer (32). The pocket region of Rb 
family members contains two domains (A and B) separated by a spacer (S), 
which is different among the Rb proteins. Rb proteins also contain a C-terminal 
domain that has been referred to as the C-pocket and is involved in E2F binding 
(33) (Figure 2). The majority of Rb binding proteins interact with the A and B 
pocket domains. Most proteins that bind to Rb share a LXCXE motif; this is 
present in the three viral oncoproteins mentioned earlier as well as the D-type 
cyclins and histone deacetylase (HDAC). Structurally and functionally, p107 and 
p130 are more related to each other than either is related to Rb. p107 and p130 
proteins also bind to E2Fs and their phosphorylation by cyclins and cdks results 
in dissociation of E2F and genes that regulate S-phase (34). However, both p107 
and p130 bind different E2Fs compared to Rb, and they regulate different E2F 
responsive genes (34). In addition, their expression pattern is unique from one 
another; Rb is expressed in both proliferating and non-proliferating cells, p107 is 
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predominantly expressed in proliferating cells and p130 is mainly expressed in 
arrested cells (34). Many years of research have suggested specific models for 
pocket protein-E2F networks. It is thought that in G0 and early G1, p107 and 
p130 form repressor complexes in conjunction with E2F4 or E2F5 at most of the 
E2F responsive promoters. At the same time, Rb is thought to bind E2F1-3 either 
at or sequestered away from E2F responsive promoters (30). Pocket proteins are 
inactivated by phosphorylation in late G1 leading to the dissociation of E2Fs; at 
this time, E2Fs 4 and 5 are thought to translocate to the cytoplasm, allowing 
E2Fs1-3 to occupy the proliferative promoters. This binding of E2Fs independent 
of the pocket proteins facilitates the expression of genes needed for DNA 
synthesis and cells enter S-phase. Thus the progression of cells from G1 to S-
phase is a stringently regulated process that involves many vital components 
(30). 
 
 
 
 
 
 
 
 
 
 7 
 
 
Figure 2. The pocket family of proteins consists of Rb, p107 and p130. 
Homology lies within the pocket domain made up of regions A and B separated 
by a spacer. All three proteins contain the C terminal domain, the region where 
E2Fs bind. Arrows indicate the many regulatory phosphorylation sites. Proteins 
containing the LXCXE mainly bind within the pocket region of these proteins. 
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1.3 Rb inactivation in cancer 
As predicted by Knudson‟s hypothesis, both alleles of the Rb gene are 
inactivated by mutation in sporadic and inherited forms of retinoblastoma tumors 
(35). The most common mutations are point mutations, small deletions, or 
insertions in the gene, which results in frameshifts and premature termination of 
the protein product (35). It is rare for a gross deletion or rearrangement of the 
gene to occur (35). Inactivation of the Rb gene leads to oncogenesis, not only in 
eye tissue, but also in osteosarcoma, small cell lung cancer (SCLC), 20-30% of 
non-small cell lung cancers (NSCLC) (36), prostate cancer, and breast cancer 
(37,38). Rb inactivation is required for the tumors to overcome the Rb mediated 
restraint on cell cycle progression. The Rb „pocket‟ is targeted by viral 
oncoproteins like adenovirus E1a (7), human papilloma virus E7 (5), and SV40 
large T antigen (6), all of which disrupt Rb‟s function.  Perturbations in the Rb 
pathway are present in almost all cancers, and several mechanisms have been 
identified for inactivating Rb. Over-expression of cyclin-D or CDK4 kinases from 
amplification, mutation, or chromosomal translocation can lead to enhanced Rb 
phosphorylation and poor prognosis (18,39-43). Also, loss or mutation in p16INK4a 
(cdk inhibitor) can induce excessive CDK4/cyclin D activity and will lead to 
increased Rb phosphorylation and inactivation. Since p16 is responsible for the 
control of cyclin D/cdk4 kinase activity, mutations or loss of p16 correlates with 
Rb activity and are often found in human cancers (37,44-47). Increased 
expression of cyclin E/cdk2 or reduced levels of the cdk inhibitor p27Kip1 also give 
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a poor prognosis in many cancers since these too will lead to increased Rb 
inactivation (18).  Another common method for Rb inactivation in cancers is 
through viral oncoprotein E7 (5,48). The tumor-promoting HPV contains at least 
two genes, E6 and E7, which encode for proteins that interfere with cell-cycle 
regulation. E7 disrupts the cell cycle via its direct binding to Rb and other 
members of the retinoblastoma family (p107 and p130). The human papilloma 
virus-16 is found associated with approximately 50 percent of cervical 
carcinomas (5). 
 
2. Downstream effectors of Rb function 
More than 100 proteins have been reported to bind to Rb. Rb interacts 
with kinases, phosphatases, transcriptional regulators, kinase regulators and 
various miscellaneous proteins (8). Although there are several Rb targets 
reported in the literature, most of the attention has been focused on the E2F 
family of transcription factors (8, 49, 50). 
 
2.1 E2F Family of Transcription Factors and Cell Cycle Regulation 
Each of the Rb family members bind to distinct members of the E2F family 
of transcription factors which regulate and drive cell cycle progression. A broad 
range of studies have revealed that Rb family members associate with a wide 
variety of transcription factors and chromatin remodeling enzymes to control 
gene expression, of which the E2F family of transcription factors are 
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predominantly studied. Our studies are focused on the regulation of E2F by Rb  
and mechanisms to prevent cell cycle progression via inhibiting Rb inactivation. 
 
2.2 Discovery of E2F and its function  
  The mammalian cell cycle is stringently regulated by growth stimulatory 
and inhibitory signals from the environment.  The transcriptional activity of the 
E2F family of proteins can respond appropriately to the wide array of signals the 
cell receives. E2F was originally discovered as a cellular activity that is required 
for the early region 1A (E1A) transforming protein of adenovirus to mediate 
transcription of the viral E2 promoter (51). Experiments later determined how 
E2F is regulated in normal cells, when Joe Nevins and colleagues determined 
that E2F is inhibited by its association with the retinoblastoma protein, Rb (51-
53). E2F family members are the key downstream targets of Rb and regulators of 
S-phase entry (54). Rb can bind directly to the transactivation domain of E2Fs 
and block their ability to activate transcription (55,56) and can recruit chromatin 
remodeling enzymes to repress E2F activity (57-59). Transcriptional repression 
by Rb is mediated through its various co-repressors including HDAC1 (60,61) 
Brg1/Brm (62), HP1 (63), SuV39H (64), PcG proteins (65) and DNMT1 (66), but 
repression is not restricted to only these co-repressors. E2F1 also induces the 
expression of the cyclin-dependent kinase inhibitor p27, resulting in negative 
feedback regulation of E2F1 transcriptional activity through the inhibition of 
cyclin-dependent kinase activity and Rb hypophosphorylation (67).  
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 In G0 and early G1, p107 and p130 bind E2F4 or E2F5 at most E2F-
responsive promoters to form a repressor complex (54). At the same time, Rb is 
thought to bind E2F1-3 either at the promoters or sequestered away from the 
promoters (30). In late G1, pocket proteins are phosphorylated causing them to 
dissociate from E2Fs. E2F4 and E2F5 relocate to the cytoplasm, and the 
promoters are then occupied by E2Fs1-3. For most promoters the binding of 
E2F1-3 coincides with recruitment of histone acetyltransferases (HATs), leading 
to acetylation of histones at the promoters facilitating transcriptional activation 
(30,68). It is the activator E2Fs that interact with various HATs, whereas Rb 
recruits histone deacteylases  (HDAC) and histone methyltransferases (69). 
Complexes of E2F family members with repressive pocket-proteins are high in 
G0 and early G1 phases of the cell cycle; these complexes are disrupted in late 
G1 (30). This allows E2Fs to induce the transcription of genes required for S-
phase entry such as cyclin E (CCNE1), cyclin A, CDC2, CDC25A, p107, RB, c-
Myc, N-Myc, B-Myb, E2F1 and E2F2 (70-72).  
 
2.3 E2F family members 
     The E2F family of transcription factors is a large and continuously growing 
family of proteins, with the first member being cloned in 1992 (E2F1) till the 
recent identification of E2F8 in 2005, totaling 9 different proteins altogether (73) 
(Figure 3). E2Fs heterodimerize with Dimerization Partner protein 1 and 2 (DP1, 
DP2) for optimal transcriptional activity and all possible combinations of E2F-DP 
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complexes can exist in vivo (74) (10). It is the specific identity of E2F and the 
proteins involved in the complex that determines the transcriptional response. 
The various E2F/DP complexes preferentially recognize the same nucleotide 
sequence – TTTCCCGC, or variants thereof (75). E2F activity is interconnected 
through complexes with any of the 9 E2Fs, 2 DP binding proteins (DP1 and DP2) 
and 3 pocket proteins (Rb, p130, p107) (76). E2Fs can be subdivided into three 
groups: the activating E2Fs, the passively repressing E2Fs and the actively 
repressing E2Fs. E2F1, E2F2 and E2F3a are the potent transcriptional activators 
that interact only with Rb and are expressed intermittently throughout the cell 
cycle (9). E2F4 and E2F5 are poor transcriptional activators and function as 
passive repressors by recruiting pocket proteins to the E2F regulated promoters 
(9). E2F4 interacts with all three pocket proteins yet E2F5 binds predominantly to 
p130 (30). The activator E2Fs are typically involved in promoting cell cycle 
progression and the repressor E2Fs function for cell cycle exit and differentiation 
(54). Unlike E2Fs 1-5, E2F6 and E2F7 lack transactivation and pocket protein 
binding domains; they actively repress transcription independent of pocket 
proteins (77). Both the E2F6 and E2F7 loci produce several alternatively spliced 
mRNAs, which encode distinct protein isoforms (78). E2F6 can repress 
transcription through binding to polycomb group (PcG) proteins (79); however, 
mechanisms underlying repression by E2F7 are still unclear. E2F7 associates 
with promoters during S and G2 phase of the cell cycle, suggesting that it may 
function to repress E2F targets once they are expressed and have executed their 
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functions (78). The newest identified member of the E2F family, E2F8, has 
transcriptional repressive functions similar to E2F7 (80).  
 
     These specific interactions between E2F transcription factors and pocket 
proteins have suggested several models of the pocket protein-E2F network. 
Once entry into S-phase has occurred, E2F1-3 continue to bind and activate 
some promoters whilst other promoters are bound by E2F1-3 only until G1-S 
transition, depending on the cellular function of the target gene (81). Certain 
studies have suggested a preferential role for E2F3a, the predominant form of 
E2F3, in regulating S-phase entry compared to other proliferative E2Fs.  The 
activator E2Fs can also overcome growth arrest signals such as TGF-β or Cdk 
inhibitors (82). It should be mentioned that the activator E2Fs do not always 
promote S-phase entry (70). The ability of E2F to induce S-phase depends 
entirely on the cellular context and the nature of the signals. 
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Figure 3. Domain structure of the E2F family. E2Fs 1-6 contain 1 DNA binding 
domain (DBD) and one DP dimerization domain (Dim). Transactivation domains 
(blue) and binding sequences for pocket proteins are found only in E2Fs1-5. 
E2F1-3 have cyclin binding domains in their N terminal region (green). E2F7 and 
E2F8 have two DNA binding domains. 
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2.4 E2F Target Genes  
     A diverse set of potential E2F target genes have been identified, shedding 
light on the many cellular functions that can be regulated by E2Fs. The list of E2F 
target genes has been growing from studies including microarray analysis and 
Chromatin Immunoprecipitation (ChIP) assays (13,14,83-93).  The known target 
genes are no longer restricted to those involved in G1/S progression and DNA 
replication, although they remain the best studied.  
 
2.4.1 Proliferative E2F target genes 
  E2F activity regulates a variety of genes required for entry into S-phase. In 
accordance with its ability to activate S-phase gene transcription, overexpression 
of the E2F1 product drove quiescent cells into S-phase (94). All three activating 
E2Fs are responsible for the expression of cyclin E and only E2F1 and E2F3 
activate the expression of Cdc6 and p107 (95). Dihydrofolate reductase is 
involved in nucleotide synthesis and is preferentially targeted by E2F2, whereas 
E2F3 is the primary activator of cdk2, a G1/S cell cycle regulator (96). Both 
ribonucleotide reductase (RRN 1, 2) and cyclin A are activated by E2F1 and 
E2F2 (96). A set of G2 expressed genes regulated by E2F, namely, cyclin B1, 
cyclin A2, Cdc20, Bub1, and Importin 2 were discovered through DNA 
microarray analysis, along with several other targets involved in checkpoint 
regulation (86). Other groups have revealed new E2F target genes by microarray 
that are involved in DNA replication, such as DNA replication protein A2, MCM 2, 
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3, 4, 5, 6, 7, and DNA polymerase  (89). The repressive E2F4/p130 complex 
(97) regulates DNA repair enzymes such as BRCA1 and RAD51. 
 
2.4.2 Apoptotic E2F target genes 
  Certain E2Fs are also equipped with pro-apoptotic functions to protect 
cells from undergoing aberrant oncogenic transformation. E2F1 appears to be 
the crucial family member facilitating E2F-dependent apoptosis (54).  The role for 
E2F1 in apoptosis was confirmed by the observation that mice lacking E2F1 
display a high incidence of tumors, implicating a role in tumor suppression 
probably by promoting apoptosis (98,99). While in certain tissues like skin and 
liver, E2F1 overexpression can result in tumor formation (100,101). A deficit in 
E2F1 can also impair the development of pituitary tumors in Rb+/- mice implying 
that E2F1 can play a tumor suppressive or oncogenic role depending on tissue 
type (102).  
 
 Different mechanisms have been identified by which E2F-1 induces 
apoptosis and the picture is becoming clearer with passing years. Interestingly, 
E2F1 can induce apoptosis in p53-dependent and independent pathways. 
Ectopic expression of E2F1 induces p53-dependent apoptosis both in vitro and in 
vivo (101,103-105) through the transactivation of p19ARF (106,107) and thus 
alleviation of MDM2-mediated degradation of p53   (106-109). In addition, E2F1 
can induce the expression of p73 (110), Apaf-1 (111), caspases (112), and pro-
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apoptotic BH3-only proteins of the Bcl-2 family (113) and thereby induces 
apoptosis through a p53-independent mechanism. Thus, pharmacologic 
activation of E2F1-mediated apoptosis in p53-deficient tumors can be explored to 
overcome the chemoresistance in these tumors.  
 
      In addition to p53 and p73, a variety of cellular proteins have been 
identified that can facilitate the induction of apoptosis by E2F1. E2F1 
downregulates the expression of Mcl-1, an antiapoptotic member of the Bcl-2 
family (114). E2F1 has also been shown to upregulate the expression of the pro-
apoptotic BH3-only proteins PUMA, Noxa, Bim, and Hrk/DP5 through a direct 
transcriptional mechanism leading to apoptosis (88,112,113,115,116). 
Expression of the E7 protein of HPV16, which disrupts Rb/E2F complexes also 
upregulates the expression of these four BH3-only proteins, implicating 
endogenous E2F in this phenomenon. Furthermore, increased Noxa and PUMA 
levels have been shown to mediate E2F1-induced apoptosis (113). HDAC 
inhibitors such as SAHA and Trichostatin A can promote E2F1-mediated 
apoptosis through the induction of the pro-apoptotic Bcl2 family member Bim as 
well as ASK1, and this apoptosis does not require p53 or p73 (117); as a result 
cancer cells with deregulated E2F1 activity are sensitive to HDAC inhibitors. 
ASK1 induction contributes to SAHA-induced apoptosis through positive 
feedback regulation of E2F1 apoptotic activity (117).  
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These studies highlight that E2F1 regulates the apoptotic machinery by 
activating a number of pro-apoptotic genes. In addition to these studies it was 
found that depletion of E2F4 and not E2F1 could enhance apoptosis induced by 
chemotherapeutic drugs in human cancer cell lines, suggesting that E2F1 and 
E2F4 act in opposing manners in drug induced apoptosis (118). Such studies 
and many more reveal the complex contributions of E2F family members to the 
biology of the cell and a panorama of apoptotic target genes that may be less 
characterized than the well understood cell cycle progression genes. 
 
2.5 E2Fs in Oncogenesis  
     The E2F family of transcription factors can execute opposing roles in 
activating or inhibiting cellular proliferation; this enables them to act as potential 
oncogenes or tumor suppressor genes.  Elegant studies in the 1990‟s were the 
first to show that E2F is inhibited through its association with Rb (51-53). Nevins 
and colleagues also discovered that overexpression of E2F1 in cell culture could 
lead to proliferation (119); it was also found that E2F1 could transform cells in 
association with other oncogenes like Ras and c-myc (119,120).  Unlike Rb, E2F 
itself is rarely found to be mutated in cancers, although recent findings have 
discovered deregulated levels or mutations of E2F family members in certain 
types of cancers (121). Gene disruption studies in mice lacking E2F family 
members clearly demonstrated the complexity and opposing roles of the E2F 
family. 
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2.5.1 Genetic Alterations of E2F in Cancer  
     Most reviews on E2F family members conclude that there are not many 
known mutations in this family of transcription factors in human cancer, and this 
holds true for the most part (122) (123). At the same time there are some reports 
indicating genetic alterations of E2F genes in cancer (124). Among the E2F 
family members, it has been the E2F3 gene, located at chromosome 6p22, which 
is frequently amplified and overexpressed in certain types of cancers like 
retinoblastoma and transitional cell carcinomas of the urinary bladder (125,126). 
In bladder cancer especially, E2F3 amplification is associated with a more 
malignant and invasive tumor (127,128). E2F3 overexpression has been 
identified in prostate, ovarian, and non-small cell carcinoma and also correlates 
with poor survival rates (129-132). There is also evidence that other E2F genes 
are involved in some cancers. The E2F5 gene is amplified in some breast 
cancers often along with c-myc and or c-mos amplification (133). It has also been 
reported that E2F4  is also mutated in a number of stomach and colon cancers 
(134-137). In addition, E2F4 protein levels are often elevated in colon cancers 
and this is associated with low levels of apoptosis (134). Moreover, deregulated 
E2F1 (transgenic mice engineered to express E2F1 in Glial cells; tg-GFAP-E2F1) 
activity in the brain increases the onset of multilineage brain tumors in mice old 
and young; this demonstrates that E2F1 functions specifically as an oncogene in 
mouse brain tissue (138). 
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   The amplification of E2F1 in cancer cell lines has been examined 
thoroughly, it has been demonstrated in esophageal, colorectal, ovarian, 
melanoma and lymph node metastasis of melanoma (139-144).  High expression 
of E2F1, E2F2 and E2F8 were linked to ovarian cancer cell lines (n=77) and also 
correlated with histopathologic grade 3 ovarian tumors (145). The clinical 
relevance of E2F family members was assessed in ovarian cancers to predict if 
E2Fs provide resistance to chemotherapy with platinum based drugs. Low 
expression of activating E2F1 or E2F2 and high expression of inhibiting E2F4 or 
E2F7 was associated with favorable disease-free and overall survival of patients 
who had undergone surgery (145). Platinum resistant tumors were associated 
with lower E2F4 and E2F7 expression when compared to platinum sensitive 
tumors indicating that their downregulation could be contributing to mechanisms 
underlying platinum resistance (145). High levels of E2F1 in cancers of the lung, 
breast and pancreas correlate with poorer outcome (76).  Conversely, it is 
reduced E2F1 expression in colon cancer, bladder cancer and diffuse large B-
cell lymphoma that correlates with a more aggressive disease (76). Even though 
there are plenty of studies that link E2F expression with cancer, it is mainly 
alterations in the Rb-E2F pathway that are common in all types of cancers. 
 
2.5.2 E2F knockout studies 
     Studies on E2F1 null mice provided novel insights into the opposing roles of 
E2F1 in oncogenesis and tumor suppression (99). E2F1-/- mice are viable and 
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fertile except, as they age these mice exhibit hyperplasia and neoplasia (98,99). 
As the mice age, a broad range of tumors was seen, including lymphomas, 
sarcomas of the reproductive tract and lung tumors (99). E2F2-/- mice die early 
due to autoimmune disease with splenomegaly, multiorgan inflammatory 
infiltrates, glomerulonephritis, and serum anti-DNA antibodies (146). The loss of 
E2F1 and E2F2 in mice results in tumor formation, primarily hematopoetic 
malignancies (147). Studies in E2F3 knockout mice revealed that although these 
mice die prematurely, the mice that do survive are significantly growth retarded. 
E2F3-/- mice have no obvious signs of tumor formation; instead they have the 
typical signs of congestive heart failure (148). A loss of both E2F1 and E2F3 did 
not increase the tumor incidence therefore demonstrating that it is E2F1 that has 
the tumor suppressive functions and not E2F3 (148). Mice lacking E2F4 
surprisingly show no abnormalities in cell proliferation or cell cycle arrest; 
however, E2F4 was essential for normal development of the mouse. Mice lacking 
E2F4 have several developmental defects including a craniofacial abnormality 
(149,150). Knockout studies on E2F5 revealed that it was also not essential for 
proliferation; instead E2F5 was required in differentiated neural tissue, as these 
mice developed hydrocephalus at 7 weeks of age (151). Mice lacking E2F6 are 
viable and healthy, they only display skeletal transformations, these mice display 
posterior homeotic transformations of the axial skeleton, which is very similar to 
what is observed in mice lacking PcG proteins, which is consistent with the ability 
of E2F6 to associate with PcG proteins (79). The phenotype of knockout E2F7 
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and E2F8 have yet to be published. It can be concluded that mice lacking 
repressive E2Fs have developmental defects but are not predisposed to 
developing tumors. Oddly enough, tumor suppressive activity is associated with 
the E2Fs that are activators of transcription and promoters of proliferation. 
 
2.6 E2Fs regulate Angiogenesis 
      While a role for E2Fs in cell proliferation and apoptosis is well established, 
their role in angiogenesis is less clear.  Recent studies raise the possibility that 
E2Fs might be contributing to the growth and progression of tumors by affecting 
angiogenesis. Overexpression of E2F1 is associated with increased tumor cell 
invasiveness and metastatic progression (152,153). Many E2F1 target genes 
include genes involved in angiogenesis such as bFGF, metalloproteinase 16 
(MMP16) and VEGF-B through a direct or indirect transcriptional regulation of the 
promoters (154). Several genes whose expression is regulated by VEGF contain 
E2F binding sites in their promoter. Human metallothionein 1G (hMT1G) is 
involved in metal metabolism and regulation of angiogenesis.  Stimulation of cells 
with VEGF led to a dissociation of Rb, p130 and p107 and an increase in 
activator E2Fs on this promoter (155). In other studies, E2F1, E2F2 and E2F3 
can activate the fibroblast growth factor receptor 2 (FGFR-2) promoter that is 
involved in angiogenesis (156).  These findings raise the possibility that even 
though E2F genes by themselves are seldom mutated in cancers, E2Fs can 
promote the growth of solid tumors by promoting angiogenesis.  
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2.7 Targeting E2F biology for cancer therapy  
     In certain circumstances, either an increase or decrease in E2F1 activity can 
inhibit tumor development; although this is entirely context dependent there is 
great potential for the design of cancer therapies targeting E2F1.  Recombinant 
adenovirus E2F1 has been shown to kill human tumor cells in vitro and in nude 
mouse models (157-162). Since deregulated E2F activity appears to be a 
common event in various malignancies, these treatments would have the 
potential to reach a broad range of cancers. It is important to note that E2F 
activity has been shown to influence chemotherapeutic response (163). It can be 
assumed that when E2F upregulates p73 and APAF-1, this could sensitize cells 
to other pro-apoptotic signals from DNA-damaging agents (110).  A key target for 
therapy could be the downstream targets in E2F1 induced apoptosis. It can be 
imagined that chemotherapeutic agents that are most active in S-phase could 
benefit from E2F activity to induce cell death. Agents such as 5-flurouracil and 
hydroxyurea that target E2F responsive genes thymidylate synthase and 
ribonucleotide reductase respectively, would benefit from forced expression of 
E2F (164,165). Experiments with E2F1 transient transfection have been shown 
to enhance the efficacy of etoposide, camptothecin, and adriamycin (166). 
Induction of DNA damage leads to E2F1 protein stability through several 
mechanisms, including phosphorylation by the ataxia-telangiectasia mutated 
(ATM) kinase, the ATM and RAD3-related (ATR) and the Chk2 kinase. E2F1 
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stability is also mediated by acetylation through p300/CREB-binding protein 
factor (P/CAF). The common deregulation of Rb/E2F pathway in human cancers 
in combination with E2F‟s apoptotic potential and stabilization after damage 
suggest that E2F1 plays an important role in tumor cells sensitivity to DNA 
damage induced cell death. In the same context, loss of E2F1 is protective and 
anti-apoptotic.   
 
  The important question is how E2Fs can be targeted to induce apoptosis 
in cancer cells without inducing cell proliferation and tumor growth. Since the 
absence of all three activating E2Fs leads to abrogation in cellular proliferation 
and mouse development (167), it appears that targeting any one of the activating 
E2Fs or all of them would be a viable mechanism to shut down tumor cell 
proliferation. Studies from the Harlow lab demonstrated how dominant negative 
mutants of DP1 that can prevent DNA binding and transcriptional regulation by 
E2F leading to cell cycle arrest in G1 (168). These studies and others collectively 
support the idea that inhibiting E2F with small molecules would inhibit cellular 
proliferation.  Introduction of peptides into human cells that functionally 
antagonize E2F DNA binding activity resulted in rapid onset of apoptosis (169). 
In another setting, peptides that bound to the DNA binding domain of E2F and 
blocked its association with DP1 resulted in a G1 block in mammalian fibroblasts 
(170). Although these experiments clearly indicate that blocking E2F DNA-
binding activity could inhibit cell proliferation and sometimes cause apoptosis, it 
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is not clear how inhibiting this interaction would selectively target cancer cells in 
comparison to normal proliferating cells.  
 
  The latest findings of new family members, new biological activities and a 
plethora of novel target genes have gained significant attention towards the E2F 
transcription factor. It is almost impossible to tie E2F to one unified model of 
transcriptional regulation. It is clear however, that this family has diverse and 
sometimes opposing activities (oncogene or tumor suppressor), the signaling 
pathways involved vary depending on the setting. The E2F field has matured and 
new discoveries will possibly conclude the specific roles of E2F in normal 
development and tumorigenesis. The possibility of using E2F effector pathways 
for enhancement of chemotherapeutic drugs may provide useful tools for drug 
development of E2F activators or repressors.  Since E2F can both stimulate 
proliferation as well as induce apoptosis, developing both E2F antagonists (to 
block proliferation) and E2F agonists (to promote apoptosis) seems a daunting 
task. It is difficult to determine whether there will be a positive or negative effect 
from these therapies. E2F family of proteins are involved in regulating an 
abundance of genes; determining which genes to shut off or turn on by E2F may 
result in complicated and insufficient therapies. A more simplistic approach to 
inhibiting proliferation would incorporate targeting upstream of E2F, i.e. Rb 
protein. 
 
3. Upstream regulators of Rb function in proliferation 
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It is well established that the Rb protein is inactivated by kinases associated 
with D and E type cyclins and this facilitates inactivation of Rb and S-phase entry 
(22). Cyclin dependent Rb regulation is well studied; it is the non-cyclin 
dependent regulation of Rb that is less understood. This section discusses the 
upstream regulators of Rb in proliferation by various stimuli including growth 
factors and nicotine. 
 
3.1 Regulation of Rb by growth factor stimulation  
  Since inactivation of the Rb protein is widespread in many forms of 
disease it is vital to understand the mechanisms involved. The 
Ras/Raf/MEK/MAPK pathway signaling pathway functions in a growth factor 
dependent manner to upregulate cyclin D1 dependent kinase activity and this in 
turn regulates Rb phosphorylation and its cell cycle functions (171). It has been 
shown that components of the MAP kinase cascade, including ERK kinases and 
Raf-1 kinase can phosphorylate Rb in response to proliferative signals (172,173). 
One study revealed that Rb is rapidly phosphorylated on Serine 795 upon 
treatment of vascular smooth muscle cells with angiotensin II or 5-hydroxy-
tryptamine and this phosphorylation could be inhibited by blocking MEK activity 
(172). In other studies, the role for MAPK cascade in inactivating Rb has been 
shown using wild type mouse embryonic fibroblasts (MEFs). MEFs containing 
wild type Rb required the activation of the MAPK cascade to enter the cell cycle 
and MEFs lacking Rb did not (65,174). 
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  It has been suggested that the MAP kinase cascade can phosphorylate 
Rb in response to proliferative signals. This cascade is initiated by ligand bound 
cell surface tyrosine kinase receptors such as epidermal growth factor receptor 
(EGFR), HER-2, vascular EGFR (VEGFR) and platelet derived growth factor 
receptor (PDGFR) leading to the activation of Ras (175,176). The tyrosine kinase 
receptor becomes phosphorylated upon ligand binding and recruits the adaptor 
protein Grb2 and SOS the guanine nucleotide exchange factor to activate Ras by 
exchanging GDP for GTP. Active Ras-GTP recruits Raf from the cytosol to the 
plasma membrane for activation by itself and other kinases, such as PAK and 
Src (177-179). Active Raf binds and phosphorylates MEK on two serine residues 
(217, 221) in the kinase domain (175). MEK then binds and phosphorylates 
ERK1 and ERK2 on Thr202/Tyr204 and Thr185/Tyr187 respectively (175). 
Activated ERK acts on several downstream substrates involved in the induction 
of numerous transcription factors and genes such as myc, c-fos, elk1, p90rsk 
(175,180-182) (Figure 4). These genes are known to be involved in promoting 
cellular proliferation, differentiation, cytoskeletal changes, cellular motility and 
extracellular matrix remodeling among many others (183-185). This pathway is 
hyperactivated in 30% of all human tumors. Although the proteins of the 
Ras/Raf/MEK/ERK pathway are mutated in many cancers, direct mutations of 
Raf-1 leading to tumorigenesis have not been identified (186,187). It is the 
downstream effector of Raf-1, ERK that impinges on all stages of malignant 
transformation (188). The potential for Raf-1 to play a huge role in tumorigenesis 
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is evidenced by its broad activation by many kinases independent of Ras, like 
PKC, Src, JAK, and Pak (177-179). Raf-1 has also been implicated in 
promoting expression of the multi-drug resistance gene MDR1 (189). There are 
several clinical trials currently underway that target Raf-1 (190,191). 
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Figure 4. Binding of growth factors to the cell surface receptor tyrosine kinases 
(RTKs) signals through adaptor proteins such as growth factor receptor bound-2 
(Grb2) and guanine nucleotide exchange factors like son-of-sevenless (SOS) 
activate Ras by exchanging GDP for GTP on Ras. Active Ras initiates membrane 
recruitment and activation of Raf, which leads to activation of dual specificity 
mitogen activated protein kinase (MAPK or MEK) and subsequently extracellular 
signal regulated kinase (ERK). Activated ERK acts on several nuclear 
transcription factors such as c-myc, c-fos and Elk-1. 
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3.1.1 Raf-1 Kinase 
  C-Raf, in particular (referred to as Raf-1), was identified in humans as the 
cellular homologue of the v-Raf oncogene (192). Shortly after, A-Raf was 
identified and had 85% sequence homology to Raf-1 in its central 100 amino 
acids (193). Identification of B-Raf, another member of the Raf family, linked all 
three Raf genes together (Figure 5); approximately 75% of the kinase domain 
was conserved on all Raf genes (194). Raf-1 is the most studied of the isoforms, 
yet it remains poorly understood. Raf-1 ranges in size from 72-74 kDa and can 
be localized in the membrane, cytoplasm as well as the mitochondria; its 
presence in the mitochondria has been correlated with a role in apoptosis 
(176,195). Raf-1 has also been shown to translocate to the nucleus upon 
mitogenic stimulation (173). Expression of Raf-1 is ubiquitous in adult tissues and 
has the highest expression in muscle, cerebellum, and fetal brain (196). Raf-1-/- 
mice show a recessive lethal phenotype, are growth retarded and die 
midgestation. The fetal livers of these mice contain a high number of apoptotic 
cells. Raf-1-/- embryos stained with platelet endothelial cell adhesion molecule 1 
(PECAM-1) revealed a reduction in the number of vessels and showed abnormal 
vascular network formation in the head region. ERK activation was not affected in 
Raf-1 knockout mice indicating that the phenotypes seen are due to lack of 
signaling through Raf-1 effector proteins independent of the ERK pathway (197). 
It has been shown that B-Raf can compensate for Raf-1 by activating MEK 
kinase raising the possibility that it is compensating for Raf-1 function in the MAP 
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kinase cascade in Raf-1 null mice. Mice containing a „knockin‟ mutation of 
endogenous 340 and 341 tyrosines to phenylalanine (raf-1FF/FF) resulting in an 
inactive form of Raf, survive to adulthood and ERK activation was not 
compromised despite the nonfunctional Raf-1 (197). MEK-independent functions 
of Raf-1 have garnered a significant amount of attention. The Bcl-2 anti-apoptotic 
protein can target Raf-1 to the mitochondria and together they cooperate in 
suppressing apoptosis (195). Bcl-2 binding protein Bag1 can activate Raf-1 in 
vitro and in vivo further increasing Raf-1‟s antiapoptotic activities (198). Pak1 
phosphorylates Raf-1 on S338 and S339, this activation by Pak is thought to 
direct Raf-1 to the mitochondria where it interacts with Bcl-2 by phosphorylating 
BAD and displacing BAD from Bcl-2 (199). Just as the role of Raf-1 in cell 
proliferation has provided therapeutic avenues for development of treatments, 
the role of Raf-1 and Bcl-2 in resistance to apoptosis may provide a target for 
inducing apoptosis in cancers with a constitutive activation of Raf-1 kinase. The 
cAMP-dependent protein kinase (PKA) is activated by second messenger cAMP. 
PKA then phosphorylates serine 43 on Raf-1 which is inhibitory for Raf-1 kinase 
activation (185).  
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Figure 5.  Domain structures of the Raf kinase family. There are three conserved 
regions on Raf kinases and remain conserved across isoforms and species. The 
N terminal CR1 domain contains a Ras binding domain (RBD and CRD). The 
CR2 domain is a serine/threonine rich domain. CR3 is the catalytic kinase 
domain. S43 and S259 in C-Raf (Raf-1), S364, S428 and T439 in B-Raf are 
inhibitory phosphorylation sites. 
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3.1.2 Raf-1 in Cancer 
    Gene rearrangements, point mutations, and truncations leading to 
constitutive activation of Raf-1 have been identified in several cancers, most 
notably in small cell lung cancer (SCLC) (200). Raf-1 overexpression has been 
linked with colon cancer and lung cancer cell lines, but not in human cancer 
tissues (175,183). One group from the Cancer Research UK Centre has linked 
Raf-1 expression with ovarian cancer cell lines. It was found that Raf-1 was the 
predominant Raf isoform accountable for regulating cell growth and apoptosis in 
ovarian cancer cell lines (201). Although the studies of Raf-1 expression have 
only been linked to cancer cell lines, it does confirm the role for Raf-1 in cancer 
development. Another study implicating Raf-1 in cancer involves the Raf-1 kinase 
inhibitor protein (RKIP). RKIP inhibits the phosphorylation of MEK by Raf-1 (202). 
In 103 human breast cancer specimens and lymph node metastasis examined, it 
was observed that RKIP expression was significantly reduced or completely lost 
in the lymph node metastasis compared to the normal levels of RKIP in the 
primary tumor (203). This suggests that the loss of an endogenous Raf-1 inhibitor 
might contribute to breast cancer metastasis. Although Raf-1 is not mutated 
extensively in cancers like Ras or p53 genes, it might contribute to tumorigenesis 
independent of Ras as well. This contention is supported by the fact that Raf-1 
can be activated by Bcl-2 protein binding protein Bag1, protein kinase C-alpha 
(PKC-) and has been linked to expression of the multidrug resistance gene 
mdr1 (176,195,198,204,205). Thus Raf-1 appears to be ideally placed to affect 
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the proliferation as well as apoptosis of cells in Ras-dependent and independent 
fashions, depending on the signaling event.  Alterations in the signaling events or 
components can potentially lead to oncogenesis, via mediation of Raf-1. 
    Several advances have been made toward understanding the potential of 
improper activation of ERK signaling. Alterations in Ras genes are the most 
frequently detected mutations in cancer. Ras alterations are associated with 90% 
of pancreatic cancer, 50% of thyroid cancer, 50% of colon cancer, 30% of lung 
cancer, and 30% of acute myeloid leukemia (AML) (206).  
 
3.1.3 Regulation of Rb by Raf-1 
  Experiments in yeast two-hybrid assays and in vitro binding assays 
revealed that Raf-1 could bind to Rb and p130, not p107 (173). Raf-1 was also 
found to bind Rb and p130 in Immunoprecipitation-Western blot experiments 
(173). The Rb-Raf-1 interaction was time course dependent; Rb-Raf-1 interaction 
is not detected in quiescent cells. Cells that were subsequently stimulated with 
serum showed Rb-Raf-1 interaction from 30 minutes to 2 hours of stimulation. 
After 2 hours of serum stimulation, Raf-1-Rb interaction was no longer detected 
(173). Rb is a nuclear protein and Raf-1 is predominantly cytoplasmic with 
activation occurring at the plasma membrane. A portion of Raf-1 was found to 
translocate to the nucleus upon serum stimulation where it bound to Rb (173) 
(Figure 6). Raf-1 could efficiently phosphorylate Rb in vitro. Raf-1 could 
inactivate Rb and reverse Rb mediated repression of E2F1 in transcriptional 
activity assays as well as S-phase entry assays.   
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Figure 6. (A) Colocalization of Raf-1 and Rb in the nucleus of HSF8 cells. 
Colocalization can be observed in yellow (bottom panel). (B) The Rb-Raf-1 
interaction is induced by serum. Extracts from HSF8 fibroblast cells stimulated 
with serum for the indicated time points were immunoprecipitated with 
monoclonal Raf-1 antibody. The presence of Rb was detected by western blot 
analysis. The Rb-Raf-1 interaction occurs from 30minutes to 2 hours of serum 
stimulation. Adapted with permission from Wang et al (173). 
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3.1.4 Raf-1 as a target for cancer therapy  
  Mutated Ras and Raf-1 are constitutively active and have transforming 
potential in vitro. It is apparent that mutations leading to Raf activation are the 
force behind many different types of malignancies and there is solid proof of 
principle for B-Raf and Raf-1 to serve as targets in cancer therapy (207). 
Although antisense oligonucleotide (ASO) therapy has been attempted and not 
been efficacious in clinical trials, this underscores the need to optimize this 
therapy in a patient specific manner (208). Poor results with ASO therapy does 
not mean that Raf-1 does not serve as an outstanding potential target, 
essentially, this therapy needs better regimens for inhibiting Raf-1 mRNA. Recent 
candidate drugs such as nanoparticles conjugated to a mutant form of Raf-1, B-
Raf inhibitors and Rb-Raf-1 protein-protein inhibitors (discussed in this thesis) will 
provide valuable insights into the molecular biology of Raf signaling in cancer 
(209-211). 
 
    The BAY-43-9006 compound, termed sorafenib, was originally identified 
as a small molecule inhibitor of Raf-1. Further characterization of the bi-aryl urea 
compound demonstrated inhibition of wild type B-Raf and mutant B-Raf kinase, 
VEGFR-2, mVEGFR-3, mPDGFR-, Flt-3, c-KIT, and FGFR-1 (212). Sorafenib 
inhibits Raf-1 and mVEGFR2 activity with an IC50 of 6nM; it‟s IC50s for B-Raf mut, 
B-Raft wt, VEGFR2, mVEGFR3, Flt-3, c-kit, p38, and mPDGFR- ranges from 
12-68nM. Sorafenib is highly selective for Raf-1 and B-Raf showing no activity 
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against downstream MEK and ERK (212). The FDA has approved Sorafenib for 
the treatment of advanced RCC since previous phase II and phase III results 
showed significant responses specifically in RCC patients. A phase II placebo 
controlled randomized discontinuation trial of sorafenib for patients with 
metastatic RCC resulted in 50% of patients being progression free at 24-weeks. 
This result showed significant disease stabilizing activity with the tolerability of 
daily therapy in comparison to the standard of care (cytokine therapy, IL-2) for 
RCC (213). RCC commonly has mutations in VHL (Von Hippel-Lindau) gene 
leading to increased production of VEGF, which makes these tumors largely 
dependent on VEGF-mediated angiogenesis (214). Sorafenib is likely functioning 
in RCC because of its ability to inhibit VEGFR and the kinases involved in 
signaling production of VEGF.  
 
3.1.5 Role of Rb-Raf-1 Interaction in Cancer 
  Given the fact that both Rb and Raf-1 play important roles in cancer cell 
signaling pathways; the Rb-Raf-1 interaction was examined in cancer. Whole-cell 
lysates were prepared from ten non-small cell lung carcinomas (NSCLC) as well 
as the adjacent normal tissue that were resected from patients. The Rb-Raf-1 
interaction was examined by IP-WB. In eight out of 10 matched pairs the Rb-Raf-
1 interaction was elevated in the tumor tissue compared to the normal adjacent 
tissue (215). ChIP assays also revealed a similar result in NSCLC tumor tissues; 
more Raf-1 was found on the proliferative promoters cdc6 and cdc25A in tumor 
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tissue compared to the normal tissue (Figure 7) (215). This suggests that the 
Rb-Raf-1 interaction might have contributed to the oncogenesis of the tumors. 
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Figure 7.  The Rb-Raf-1 interaction is elevated in tumor samples. (A) NSCLC 
tumors (T) contained more Rb-Raf-1 complexes than adjacent normal tissue (N). 
Rb-Raf-1 interaction was assessed by IP-WB on nuclear extracts. (B) ChIP 
assays on human NSCLC tumor samples show that more Raf-1 was present on 
both cdc6 and cdc25A promoters in tumor samples compared to adjacent normal 
tissue. Adapted with permission from Dasgupta et al (215). 
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3.1.6 Disruption of the Rb-Raf-1 Interaction 
  The Rb-Raf-1 interaction was found to occur on amino acids 10-18 in the 
N-terminal region of Raf-1 (209). Raf-1 seems to function similar to viral 
oncoproteins; stable binding is required for inactivation of Rb and Raf-1 binds in 
the pocket domain of Rb. One major difference is viral oncoproteins dissociate 
E2F1 from Rb and Raf-1 does not.  A peptide corresponding to amino acids 10-
18 on Raf-1 was created to examine disruption of the Rb-Raf-1 interaction. The 
peptide sequence is ISNGFGFK, a C was added to the carboxyl terminal end to 
allow coupling to the carrier molecule penetratin.  The Raf-1 peptide (1M) could 
inhibit the Rb-Raf-1 interaction without inhibiting the binding of other proteins to 
Rb or Raf-1 (209). The Raf-1 peptide pen-conjugate could disrupt the binding of 
Rb-Raf-1 in cells; this was shown in confocal colocalization experiments as well 
as several other biochemical assays (Figure 8). Kinetic experiments showed that 
the Rb-Raf-1 interaction occurred as early as 30 minutes from serum stimulation 
up to 4 hours, and this binding preceded the binding of cyclin D. Rb 
phosphorylation was also found at two hours of serum stimulation (time when 
Raf-1 is found to bind to Rb). More surprisingly, the inhibition of Rb-Raf-1 with 
the Raf-1 peptide pen-conjugate could significantly inhibit Rb phosphorylation 
even up to 16 hours post serum stimulation (209).  Since Raf-1 binding to Rb 
does not cause E2F1 to dissociate yet could reverse Rb mediated repression of 
E2F1, it was examined how Raf-1 de-represses E2F1. Chromatin 
Immunoprecipitation assays (ChIPs) and Immunoprecipitation western blot 
 41 
assays (IP-WBs) revealed that Raf-1 binding to Rb led to the dissociation of 
chromatin remodeling protein Brg1 from Rb. Although other corepressors are 
present, Raf-1 seems to specifically dissociate Brg1 from the promoters of E2F 
regulated genes. Treatment with the Raf-1 peptide pen-conjugate led to Brg1 
recruitment on proliferative promoters. There was no change in the binding of 
HDAC1 and HP1. Disruption of the Rb-Raf-1 interaction with the Raf-1 peptide 
pen-conjugate also significantly inhibited proliferation (209). The peptide pen-
conjugate could inhibit 50% of cells from entering S-phase. The peptide pen-
conjugate efficiently inhibited angiogenic tubule formation in matrigel assays as 
well as adhesion, migration and invasion of human aortic endothelial cells 
(HAECs)(209). An anti-angiogenic and anti-proliferative agent can be expected to 
inhibit tumor growth since these are hallmarks of cancer. A549 human xenograft 
tumor growth was inhibited approximately 80% from treatment with the Raf-1 
peptide pen-conjugate intratumorally (209). These results clearly demonstrated 
that disruption of Rb-Raf-1 interaction could efficiently inhibit tumor growth and 
angiogenesis in vivo. It can be assumed that small molecules that are capable of 
inhibiting the Rb-Raf-1 interaction have therapeutic potential for controlling 
proliferative disorders such as cancer. Essentially, the abovementioned studies 
led to the screening of small molecule libraries for compounds capable of 
inhibiting Rb-Raf-1 interaction, these experiments and more will be discussed in 
chapter 3 of this thesis. 
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Figure 8. The penetratin-Raf-1 conjugate can inhibit Rb-Raf-1 interaction in 
intact cells. (A) U2-OS cells immunostained with Raf-1 (Red) and Rb (green) 
were visualized by confocal microscopy. Serum starved cells show no 
association of Raf-1 with Rb. Serum stimulation induces Raf-1 to translocate to 
the nucleus where it binds Rb, colocalization is seen in yellow. The presence of 
1M of the Raf-1 peptide conjugate could inhibit the binding of Raf-1 to Rb.  The 
Raf-1 scrambled peptide has no effect on Raf-1 Rb binding. (B) Nuclear and 
cytosolic extracts revealed that Raf-1 peptide conjugate does not affect the 
nuclear translocation of Raf-1. Adapted with permission from Dasgupta et al 
(209). 
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3.2 Growth factor independent regulation of Rb  
The Rb protein contains approximately 18 potential phosphorylation sites, 
cdk4/6 has been shown to target 4 residues C-terminal to the pocket domain 
(216,217). Cyclin D associated kinases; cyclin E-cdk2 complexes have also been 
shown to modulate Rb function. Although it has been shown that there is a clear 
link between growth factor stimulated Ras/MAPK pathway and Rb 
phosphorylation-cell cycle, other non-growth factors regulating this pathway have 
not been defined. Studies involving hormones and neurotransmitters have also 
revealed a link between Ras/MAPK signaling and Rb-E2F pathway. Treatment 
with Angiotensin II or Serotonin could induce phosphorylation of serine 795 on 
Rb and this activation was mediated by CDK4 and MAPK pathway (172). 
Stimulation with either Serotonin or Angiotensin II also resulted in dissociation of 
E2F from Rb (172). These studies support the idea that Rb is regulated during 
growth factor dependent stimulation as well as non growth factor activation. 
 
3.2.1 Rb inactivation upon nicotine stimulation via nicotinic acetylcholine 
receptors (nAChRs) 
Non-small cell lung cancer (NSCLC) is associated with 80% of the total 
number of lung cancer cases and is strongly associated with tobacco use. There 
are several carcinogenic compounds found in tobacco smoke such as 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N‟-nitrosonornicotine 
(NNN); these molecules can form DNA adducts leading to mutations in vital 
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genes like Ras, p53, and Rb (218,219). The carcinogen NNK that is structurally 
related to nicotine has been shown to induce proliferation and angiogenesis 
through nicotinic acetylcholine receptor subunits (nAChRs). 
 
nAChRs are pentameric proteins consisting of nine  subunits (2-10) 
and three  subunits (2-4) in non-neuronal cells;  and  subunits are present in 
neuronal systems (220). Studies in recent years have shown that nicotinic 
receptors are also present in a wide variety of non-neuronal tissues, including 
human bronchial epithelial cells, human endothelial cells and astrocytes (220-
223).  These observations led to the realization that signaling through the 
nicotinic acetylcholine receptors could have functional roles in non-neuronal cells 
as well. The finding that nAChRs are present on non-neuronal cells was followed 
by the observation that nicotine could induce the proliferation of endothelial cells 
(221,224).  Further, it was found that nicotine and structurally related carcinogens 
like NNK could induce the proliferation of a variety of small cell lung carcinoma 
cell lines (225,226).  Studies from Dr. Schuller‟s lab revealed that nicotine 
stimulation induces the activation of Raf-1 (227).  In addition to these studies, it 
has been shown that persistent nicotine exposure stimulates Ras signaling and 
MAPK activation in mouse epithelial cells (228). Nicotine was also shown to 
induce the cyclin D1 promoter and therefore cell cycle (228). 
 
   Recently, our lab has demonstrated the how nicotine signaling involves 
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the Rb-E2F pathway and promotes cell cycle entry. Nicotine stimulation of 
NSCLC cell lines leads to the binding of -Arrestin to the -7 nAChR, which in 
turn activates Src kinase (215). The activation of Src leads to the activation and 
binding of Raf-1 to Rb.  Raf-1 can bind to Rb and initiate its inactivation 
facilitating cell cycle progression (Figure 9). Nicotine stimulation resulted in 
dissociation of E2F1 from Rb and this correlated with the induction of cyclin/cdk 
activity as well as Rb phosphorylation. In response to nicotine stimulation, 
proliferative promoters cdc6 and cdc25A were found to have more E2F1 and 
dissociation of Rb (215).  Nicotine functions via the 7 nAChR upstream of Rb-
E2F pathway facilitating cell cycle progression.  
 
This led to the hypothesis that nicotine might be playing a direct role in the 
progression of human lung cancers.  While there is no evidence that nicotine 
contributes to the induction of tumors, it has been demonstrated that nicotine 
promotes the growth of solid tumors in vivo, suggesting that nicotine might be 
playing a more important role in the progression of tumors already initiated 
(229,230). Chapter 4 focuses on the role of nicotine in tumor growth and 
metastasis. 
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Figure 9. Schematic predicting the proliferative signaling by nAChRs in NSCLC 
cells. Nicotine stimulation causes the assembly of oligomeric complexes 
involving -Arrestin, Src and nAChRs, facilitating the activation of Src.  This leads 
to the activation of Raf-1, which binds to Rb; activation of MAPK and cyclins/cdks 
also occur. The activation of Src facilitates the binding of Raf-1 to Rb and 
multimeric complexes containing Rb, Raf-1 and E2F1 occupy proliferative 
promoters. Sustained mitogenic signaling leads to the dissociation of Raf-1 and 
Rb, while E2F remains bound to the promoter facilitating S-phase entry. Adapted 
with permission from Dasgupta et al (215). 
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4. Upstream regulators of Rb-E2F Function in Apoptosis 
Several attempts have been made to understand how extracellular signals 
modulate Rb and E2F function to bring about cellular apoptosis. It has been 
suggested that suppression of apoptosis may be the primary function of Rb, 
independent of its anti-proliferative activity. It has been shown that Rb is 
inactivated upon apoptotic signaling as well as proliferative signaling (231-233). 
 
 
4.1 Apoptotic Signaling Pathways Regulate Rb Function 
 In an earlier study, experiments were done to assess whether kinases 
involved in non-proliferative pathways like JNK and p38 affect Rb/E2F function 
(234). These two kinases were found to have opposite effects on E2F function: 
the stress-induced kinase JNK1 inhibits E2F1 activity whereas the related p38 
kinase reverses Rb-mediated repression of E2F1. JNK1 could phosphorylate 
E2F1 in vitro reducing the DNA binding activity. Phosphorylation of Rb by p38 
kinase upon Fas stimulation resulted in the dissociation of E2F and increased 
transcriptional activity. The inactivation of Rb by Fas was blocked by SB203580, 
a p38-specific inhibitor, as well as a dominant-negative p38 construct; cyclin-
dependent kinase (cdk) inhibitors as well as dominant-negative cdks had no 
effect (235). These results suggest that Fas-mediated inactivation of Rb is 
mediated via the p38 kinase, independent of cdks. The Rb/E2F-mediated cell 
cycle regulatory pathway appears to be a normal target for non-mitogenic 
signaling cascades and could be involved in mediating the cellular effects of such 
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signals (234,236). 
 
       It has also been shown that the apoptotic signal-regulating kinase 1 
(ASK1) kinase can modulate apoptotic signaling by affecting Rb function (237).  It 
was found that ASK1 kinase had to overcome the anti-apoptotic effects of Rb to 
induce cell death.  ASK1 was found to directly associate with Rb protein leading 
to its dissociation from specific pro-apoptotic promoters like p73.  Release of Rb 
from pro-apoptotic promoters coincided with its enrichment on proliferative 
promoters; it appears that this is a mechanism to prevent inappropriate cell cycle 
entry in adverse conditions. This suggests that the ASK1-p38 kinases are able to 
modulate cellular apoptosis by modulating Rb function as well as the 
transcriptional activity of E2F1 (Figure 10). It can be assumed that during 
mitogenic scenarios, Rb binds to prosurvival kinases such as Raf-1 and 
cyclins/cdks to promotes proliferation. In the presence of apoptotic stimuli, Rb 
binds to apoptotic kinase ASK1. Even though both of these interactions can 
inactivate Rb and activate E2F1 transcriptional activity, they induce different 
promoters: such as p73 (apoptotic stimuli) or cdc25A (mitogenic stimuli)(237).  
 
     One very interesting finding is that the specific stress stimulus of tumor 
necrosis factor-alpha (TNF-) regulates Rb function very differently depending on 
the cellular context. TNF- is a pleiotropic inflammatory cytokine and has been 
shown to play two very important opposing roles in both inhibition of endothelial 
 49 
cell proliferation and enhancement of apoptosis, yet stimulation of vascular 
smooth muscle cell proliferation and migration (238,239). TNF-, like other 
chemoattractants such as PDGF, stimulates VSMC migration through the MAPK 
pathway (240).  It has been shown that TNF can induce Rb phosphorylation via 
p38 and ASK1 kinases, leading to apoptosis in most cells, including human aortic 
endothelial cells (HAECs). One intriguing exception to this is in vascular smooth 
muscle cells (VSMCs), where TNF- is capable of inducing proliferation. 
Migration of VSMCs is a crucial event in the formation of vascular stenotic 
lesions. TNF- is upregulated by VSMCs in atherosclerosis and following 
angioplasty. The VSMC response to TNF- provides a therapeutic possibility to 
prevent VSMC proliferation and therefore block restenosis. Chapter 5 reveals 
new insights into TNF- induced VSMC proliferation via Rb-Raf-1 and MAPK 
pathways. 
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Figure 10. A model for the Rb/E2F pathway in cell proliferation and apoptosis in 
AoSMCs and HAECs upon TNF- stimulation. In AoSMCs, TNF- stimulates 
binding of Raf-1 to Rb, facilitating its inactivation and stimulating cell cycle 
progression. In HAECs, TNF- stimulates the binding of ASK1 to Rb, leading to 
inactivation and E2F1 inducing apoptosis through p73. The inactivation of Rb 
releases E2F1, which can bind to proliferative or apoptotic promoters and make 
vital decisions on cell survival or death. 
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5. Summary 
  Rb plays a central role in cellular homeostasis. It acts as the main 
component of a very complex network in which cell cycle is regulated; it can be 
imagined that regulation of Rb is often disrupted in various diseases. Studies in 
mice genetically deficient in Rb in all hematopoietic cells revealed a significant 
role for Rb in hematopoiesis; suggesting that Rb is involved in many different 
types of cells in the body (241). Rb has also been linked to atherosclerosis and 
restenosis. In addition to cancer and heart disease, Rb/E2F pathway is found to 
be altered in human and mouse ulcerative colitis (Crohn‟s disease) (242). 
Studies from our laboratory have been focused specifically on Rb-E2F signaling 
pathways in lung cancer and heart disease, namely atherosclerosis.  
 
Development of atherosclerosis is a stringently regulated and complex 
process that occurs as a result of aberrations in endothelial cell and smooth 
muscle cell (SMCs) function. Endothelial cells (EC) form the lining of the blood 
vessels and the heart, functioning as a barrier by regulating permeability, 
thrombogenicity, and production of growth inhibitory molecules (243). Endothelial 
cells also respond to mechanical forces. ECs are contact inhibited under normal 
conditions; but when endothelial cells sense an injury such as abrasion of a 
vessel, they proliferate and migrate leading to reendothelialization at sites of 
injury (244). At the same time, vascular smooth muscle cells proliferate and 
 52 
migrate from the injured arterial wall into the vessel lumen leading to vessel 
thickening and occlusion, called restenosis (245). Intimal hyperplasia 
characterized by VSMC proliferation and extracellular matrix (ECM) deposition is 
a major process contributing to restenosis (246). Atherosclerotic lesions can be 
blocked if inhibition of VSMCs is effective (243).  Several growth factors and 
cytokines are capable of stimulating VSMC migration and proliferation, such as 
platelet derived growth factor (PDGF), which plays a vital role in the development 
of restenosis (247). VSMC proliferation leads to downstream activation of 
Raf/MEK/ERK signaling pathway, which in turn inactivates Rb to induce cell 
proliferation. We have shown that an effective way to inhibit endothelial cell 
migration and invasion is through disruption of Rb-Raf-1. Targeting Rb-Raf-1 with 
small molecule inhibitors to prevent VSMC migration and invasion will serve as 
viable targets for drug therapy for vascular proliferative disorders.  
 
The studies described indicate the role of Raf-1 binding to and regulating 
Rb‟s function. Mitogenic and non-mitogenic stimulation have been shown to 
induce this interaction in a variety of cell types (209,215). Raf-1 can bind and 
inactivate Rb and this facilitates further phosphorylation by cyclins/cdks and cell 
cycle progression. The Rb-Raf-1 interaction is elevated in NSCLC tumors 
suggesting this interaction plays a role in the oncogenesis of the tumors (215). 
The Rb-Raf-1 interaction may be regulating two very important hallmarks of 
cancer; proliferation and angiogenesis. Targeting the protein-protein interaction 
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with the Raf-1 peptide could prevent S-phase entry, inhibit angiogenesis and 
tumor growth in nude mice (209). Disruption of this interaction with peptides or 
small molecule inhibitors is a viable alternative to controlling proliferative 
disorders such as cancer and atherosclerosis (Figure 11).  
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Figure 11. Schematic depicting the Raf-1-Rb signaling pathway. Small molecule 
inhibitors capable of disrupting the Rb-Raf-1 interaction is a viable strategy to 
prevent cell cycle progression, invasion, migration, angiogenesis and tumor 
growth. 
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Chapter 2: Materials and Methods 
 
Cell culture and transfection 
       The human promyelocytic leukemia cell line U937 was cultured in RPMI 
(Mediatech) containing 10% fetal bovine serum (FBS; Mediatech). U2-OS, Saos-
2, PANC1, CAPAN2, A375, DU145, SK-MEL-5, SK-MEL-28, MDA-MB-468, 
H1299 and MDA-MB-231 cell lines were cultured in Dulbecco modified Eagle 
Medium (DMEM; Mediatech) containing 10% FBS.  A549 cells and A549 shRNA 
Rb cell lines were maintained in Ham F-12K supplemented with 10% FBS. 
ShRNA cells lines were maintained in media containing 0.5g/ml puromycin. 
Line1, H1650, H596, H2172, PC-9, LNCap, PC3 and Aspc1 cell lines were 
cultured in RPMI (Gibco) containing 10% FBS. Human aortic endothelial cells 
(HAECs) and human umbilical vein endothelial cells (HUVECs) were obtained 
from Lonza and cultured in endothelial growth medium, supplemented with 5% 
FBS, according to the manufacturer‟s instructions. Human aortic smooth muscle 
cells were obtained from Lonza and cultured in smooth muscle basal medium, 
supplemented with growth factors and 5% FBS, according to manufacturer‟s 
instructions. U251MG and U87MG glioma cell lines were maintained in DMEM 
supplemented with non-essential amino acids, 50mM -mercaptoethanol, and 
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10% FBS. Nicotine (Sigma) was dosed at 1M concentration for all nicotine 
experiments. TNF- (Promega) was added at 100ng/ml. PDGF (Biosource) was 
added at 100ng/ml concentration. ShRNA cell lines were made by stably 
transfecting A549 cells with two different shRNA constructs that specifically 
target Rb obtained from a shRNAmir library from Open Biosystems, Huntsville, 
AL.  
In vitro drug library screening  
       ELISA 96-well plates (Nunc) were coated with 1g/ml of GST Raf-1 (1-
149aa) overnight at 4C. Subsequently the plates were blocked for 1 hour. GST 
Rb at 20g/ml was pre-incubated at RT for 30 minutes in the presence or 
absence of the compounds at 20M. This GST Rb was added to the plate and 
incubated for 90min at 37C. The amount of Rb bound to Raf-1 was detected by 
Rb polyclonal antibody (Santa Cruz) 1:1000 incubated for 60 min at 37C. 
Donkey-anti-rabbit-IgG-HRP (1:10,000) was added to the plate and incubated at 
37C for 60 minutes. The color was developed with orthophenylenediamine 
peroxidase substrate tablets (Sigma) and the reaction was terminated with 3M 
H2SO4. Absorbance was read at 490nm. To determine disruption of Rb to E2F1, 
Phb, or HDAC1 the above protocol was used with the exception of coating GST 
Rb on the ELISA plate and adding the drugs in the presence or absence of GST 
E2F1, Phb, or HDAC1. E2F1 monoclonal antibody (Santa Cruz) (1:2000) was 
used to detect the amount of Rb bound to E2F1. Prohibitin monoclonal antibody 
(NeoMarkers) was used at 1:1000 to detect the amount of Rb bound to 
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Prohibitin. HDAC1 polyclonal antibody (Santa Cruz) was used at 1:1000 to detect 
the amount of Rb bound to HDAC1.  For disruption of Mek-Raf-1 binding ELISAs, 
Raf-1 1g/ml was coated on the plate and GST Mek (20g/ml) was incubated in 
the presence or absence of the compounds for 30 minutes at room temperature. 
Mek1 polyclonal antibody (Cell Signaling) was used at 1:1000 to detect the 
binding of Raf-1 to Mek1. The IC50 concentrations for the Rb-Raf-1 inhibitors 
were determined by plotting with Origin 7.5 software. 
 
Lysate preparation, immunoprecipitation, and Western blotting 
       Lysates from cells treated with different agents were prepared by NP-40 lysis 
as described earlier (209). Tumor lysates were prepared with T-Per tissue lysis 
buffer (Pierce) and a Fischer PowerGen 125 dounce homogenizer (248). 
Physical interaction between proteins in vivo was analyzed by 
immunoprecipitation-western blot analyses with 200μg of lysate and 1μg of the 
indicated antibody as previously described. Polyclonal E2F1, B-Raf, ASK1, 
Cyclin D and E were obtained from Santa Cruz Biotechnology. Monoclonal Rb 
and Raf-1 were supplied by BD Transduction laboratories. Polyclonal antibodies 
to phospho-Rb (807,811), phospho-Raf- (338), phospho-JNK, phospho ERK 1/2 
and  phospho Mek1/2 were supplied by Cell Signaling. 
 
CAT assays 
      Assays for chloramphenicol acetyltransferase (CAT) and β-galactosidase 
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were performed using standard protocols (173). Cells were transfected by CaCl2 
and treated with drug asynchronously for 24 hours. 
 
Chromatin Immunoprecipitation (ChIP) assay 
       A549 cells were rendered quiescent by serum starvation and re-stimulated 
with serum for 2h or 16h in the presence or absence of RRD 251 at 20M. Cells 
were cross-linked with 1% formaldehyde for 10 minutes at room temperature. 
Subsequently, the cells were harvested and ChIP lysates were prepared (209). 
Immunoprecipitations were conducted using antibodies against E2F1, Rb, Raf-1, 
Brg1, HP1, and HDAC1 and the association with specific promoters detected by 
PCR as previously described. Rabbit anti-mouse secondary antibody was used 
as the control for all reactions. The sequences of the PCR primers used in the 
PCRs were as follows: cdc6 promoter (forward primer), 5‟- 
GGCCTCACAGCGACTCTAAGA-3‟; and cdc6 promoter (reverse primer), 5‟-
CTCGGACTCACCACAAGC-3‟ TS promoter (forward primer), and 5'-GAC GGA 
GGC AGG CCA AGT G-3' TS promoter (reverse primer). The cdc25A and c-fos 
primers are described in (209).  
 
Real-time PCR 
      A549 cells were subjected to serum starvation or treatment with RRD-251. 
Unstimulated serum starved cells were used as a control. Total RNA was isolated 
by an RNeasy miniprep kit from QIAGEN following the manufacturer's protocol. 
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One microgram of RNA was DNase treated using RQ1 DNase (Promega), 
followed by first-strand cDNA synthesis using the iScript cDNA synthesis kit (Bio-
Rad). A fraction (1/20) of the final cDNA reaction volume was used in each PCR 
(249). Primers sequences are as follows: 5'-CTG CCA GCT GTA CCA GAG AT-
3' (TS forward primer), 5'-ATG TGC ATC TCC CAA AGT GT-3' (TS reverse 
primer), 5'-CCC CAT GAT TGT GTT GGT AT-3' (Cdc6 forward primer), 5'-TTC 
AAC AGC TGT GGC TTA CA-3' (Cdc6 reverse primer), 5'-CTC AAC ACG GGA 
AAC CTC AC-3' (18S forward primer), and 5'-AAA TCG CTC CAC CAA CTA 
AGA A-3' (18S reverse primer). Real-time PCR was performed using a Bio-Rad 
iCycler. 
 
In vitro kinase assay 
      The kinase reaction for Raf-1 was carried out with 100ng of Raf-1 (Upstate 
Signaling), 0.5g of MEK1 (Upstate) as the substrate or 0.1g Rb (QED 
Biosciences), 10M ATP, 10Ci of [-32P] ATP in the kinase assay buffer in the 
presence or absence of the drugs at 30°C for 30 minutes. 1M of BAY-43-9006 
was used as a control and 20M RRD-251 was used. Cyclin D and E kinase 
assays are described in reference (209). 
 
Proliferation assays 
      Bromodeoxyuridine (BrdU) labeling kits were obtained from Roche 
Biochemicals. Cells were plated in poly-D-lysine coated chamber slides at a 
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density of 10,000 cells per well and rendered quiescent by serum starvation for 
24 hours. Cells were then re-stimulated with serum in the presence or absence of 
the indicated drugs for 18h. S-phase cells were visualized by microscopy and 
quantitated by counting 3 fields of 100 in quadruplicate. For nicotine treatments, 
Line1 cells were serum starved for 72 hours and subsequently stimulated with 
1µM Nicotine (Sigma). 
 
Soft Agar Colony Formation assays 
      Soft agar assays were done in triplicate in 12-well plates (Corning). First, the 
bottom layer of agar (0.6%) was allowed to solidify at room temperature. Next the 
top layer of agar was (0.3%) was mixed with 5,000 cells per well and the 
indicated drug.  The drugs were added twice weekly in complete media to the 
agar wells. Colonies were quantified by staining with MTT 1mg/ml for 1hour at 
37C. 
 
Matrigel Assays 
       Matrigel (Collaborative Biomedical Products) was used to promote the 
differentiation of HUVECs or HAECs into capillary tube-like structures (209). A 
total of 100l of thawed Matrigel was added to 96-well tissue culture plates, 
followed by incubation at 37C for 60 minutes to allow polymerization. 
Subsequently, 1 X 104 HAECs or HUVECS were seeded on the gels in EGM 
medium supplemented with 5% FBS in the presence or absence of 20M 
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concentrations of the indicated compounds, followed by incubation for 24 hours 
at 37C. Capillary tube formation was assessed using a Leica DMIL phase 
contrast microscope. 
 
Ex-vivo Rat Aorta Ring Angiogenesis assays 
      Forty-eight well tissue culture plates were coated with 200l of Matrigel and 
allowed to polymerize for 1 hour at 37C. Thoracic aortas were excised from 8-10 
week old male Sprague-Dawley Rats (250-300g) (250). The fibroadipose tissue 
was removed. The aortas were rinsed several times with EGM-2 (Clonetics), 
sectioned into 1mm rings and placed on the matrigel-coated wells. The rings 
were covered with an additional 200l of Matrigel and allowed to polymerize. The 
rings were cultured in EGM-2 media in the presence or absence of 20M of 
RRD-251. The media and drug were supplemented twice a week for one week. 
The Aortic rings were photographed on day 7 using a Leica phase contrast 
microscope. Quantitation of microvessel growth was done using Image Pro Plus 
(v.6.0) software and values are reported as microvessel area. 
 
In vivo Matrigel Plug Angiogenesis assays 
       In vivo matrigel plug assays were carried as previously described (251). 
Cooled liquid matrigel (Collaborative Biomedical Products) (300l) was injected 
subcutaneously into both flanks of nude mice. The next day, the mice were 
separated into two groups; one group received the vehicle (PBS/DMSO) every 
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day by i.p. injection and the second group received RRD-251 50 MPK daily by 
i.p. injection. The mice were treated for 7 days. At 7 days post matrigel injection, 
the mice were injected with 100l of 100 MPK FITC-Dextran (Sigma) through the 
tail vein. 30 minutes later, the mice were euthanized and the matrigel plugs were 
removed and fixed in buffered formalin. Each sample was visualized and 
searched for areas of vessel formation. Two images were captured per matrigel 
plug. Samples were viewed with a Leica DMI6000 inverted microscope, TCS 
SP5 confocal scanner, and a 20X/0.7NA Plan Apochromat objective (Leica 
Microsystems, Germany).   An Argon 488 laser line was applied to excite the 
samples and tunable filters were used to minimize background fluorescence.  
Image sections at 2.0 µm were captured with photomultiplier detectors 3D 
projections were prepared with the LAS AF software version 1.6.0 build 1016 
(Leica Microsystems, Germany).  Quantification of intensity and angiogenesis 
was performed using Image Pro Plus 6.2 (Media Cybernetics, Inc., Maryland). 
Average intensity per pixel is plotted as percent angiogenesis in each image, 
(n=12). Each image is representative of areas of vessel formation throughout 
entire matrigel plug. After confocal imaging, samples were paraffin blocked and 
stained with H&E. H&E images shown display ¼ of the matrigel plug. 
 
Quantitation of VEGF 
Asynchronously growing A549 cells were treated with RRD-251 (20 and 
50M) for 24 hours. Aliquots of media (1mL) were taken and stored at -20ºC for 
 63 
later analysis. ELISA to human VEGF (Biosource, Invitrogen) was performed 
following manufacturer‟s protocols. Concentrations were plotted against the 
standard curve. 
 
Animal Studies 
       Nude mice (Charles River, Wilminton, MA, USA) were maintained in 
accordance with Institutional Animal Care and Use Committee (IACUC) 
procedures and guidelines. A549 or H1650 cells were harvested and 
resuspended in PBS, and then injected s.c. into the right and left flanks (10 x 106 
cells per flank) of 8-week old female nude mice as reported previously (209,248). 
For SK-MEL-28 xenograft experiments, SK-MEL-28 cells were resuspended in 
1:1 PBS/Matrigel solution.  When tumors reached about 100-200mm3, animals 
were dosed intraperitoneally (i.p.) or orally by gavage with 0.1ml solution once 
daily. Control animals received a vehicle, whereas treated animals were given 
RRD-251 at the indicated doses. The tumor volumes were determined by 
measuring the length (l) and the width (w) and calculating the volume (V= lw2/2) 
as described previously. Statistical significance between control and treated 
animals were evaluated using Student‟s t-test.  
 
Immunohistochemistry staining 
       Upon termination of xenograft anti-tumor experiments, tumors were 
removed and fixed in 10% neutral-buffered formalin before processing into 
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paraffin blocks. Tissue sections (5m thick) were cut from the blocks and stained 
with H&E, Ki-67, CD31, phospho-Rb, -Catenin and E-cadherin antibodies. 
Paraffin sections were rehydrated to PBS and processed using the following 
protocols. Sections were rinsed in dH2O, and then subjected to microwave 
„antigen retrieval‟ for 20 minutes on 70% power, with a 1 minute cooling period 
after every 5 minutes, in 0.01 M sodium citrate, pH 6.0. Sections were cooled for 
20 minutes, rinsed 3 times in dH2O, twice in PBS and incubated in 5% normal 
goat serum for 30 minutes. Sections were incubated in primary antibody for 1 
hour in 5% normal goat serum, rinsed 3 times in PBS. For color development the 
slides were treated with ABC kit from Vector labs, rinsed in dH2O, and developed 
using DAB as chromogen. After a final rinse in dH2O, sections were lightly 
counterstained in hematoxylin, dehydrated, cleared and coverslipped. Tissue 
sections were stained with hematoxylin and eosin (H&E) using standard 
histological techniques. Tissue sections were also subjected to immunostaining 
for CD31 (BD Biosciences, San Diego, CA, USA) using the avidin–biotin 
peroxidase complex technique. Mouse monoclonal antibody was used at 1 : 50 
dilution following microwave antigen retrieval (four cycles of 5 min each on high 
in 0.1 M citrate buffer . Stained slides were scanned on an Ariol SL-50 Automatic 
Scanning System and whole tumor sections were quantitated using Image Pro 
Plus (v.5.1.0) software. 
 
Statistical Analysis 
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       Statistical analysis was performed using one tailed Student‟s t-test. Values 
were considered significant when the p value <0.01. Exact p values are reported. 
 
In vitro binding assays 
Glutathione S-transferase (GST) fusions of Rb and Raf-1 have been 
previously described (209,237). 35-S labeled Raf-1 proteins were generated by in 
vitro transcription translation in rabbit reticulocyte lysate according to the 
manufacturer‟s instructions (Promega, Madison, WI). First, 8l of the lysates 
were incubated with the GST-Rb beads in 200l of protein binding buffer (20mM 
Tris [pH 7.5], 50mM KCL, 0.5mM EDTA, 1mM DTT, 0.5% NP-40, 3mg/ml BSA) 
at 4 C for 2 hours as described earlier (209,237). The input lanes contained 
approximately one fourth of that used in the binding assay. Peptide synthesis 
was carried out by Ted Gauthier at the USF Chemistry department. Alanine scan 
of Peptide consisted of the 8 amino acid peptide with an alanine replacing one 
amino acid at each position on the peptide. 
 
Cell Viability Assays 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] was 
purchased from Sigma and was constituted at 10mg/ml in sterile PBS. Cells were 
plated at densities of 3,000-5,000 cells per well in 96-well plates.  Cells were 
treated asynchronously with several inhibitors at varying concentrations. DMSO 
was used as the control. 24-48 hours post-treatment, MTT was added to the 
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wells and allowed to metabolize for 30 min-2 hours. Media was carefully 
aspirated out from the wells and DMSO was added to solubilize the crystals. 
Absorbance was measured at 540nM on a Victor plate reader. 
 
Apoptosis Assays 
Cells (10,000/well) were plated in poly-D-lysine coated chamber slides. 
Drug treatment on asynchronous cells was for 18-24 hours and subsequently 
fixed with formalin. Apoptosis was measured using a TUNEL assay kit 
(Promega). Parallel experiments were also set up in 10cm tissue culture dishes 
and apoptosis was confirmed by immunoblotting for PARP (Cell Signaling). 
 
Double Immunofluorescence Assays 
U2-OS osteosarcoma cells were plated on poly-D-lysine coated chamber 
slides and rendered quiescent by serum starvation for 48 hours. Thereafter, the 
cells were re-stimulated with serum for 2 hours in the presence or absence of 
RRD-251 at 20M concentration. Cells were fixed with 4% paraformaldehyde 
and permeabilized with PBS containing 0.2% Triton-X-100. Monoclonal anti-Rb 
(1:50) and polyclonal anti-Raf-1 (1:200) were added in blocking buffer, and 
incubated on the cells overnight at 4ºC.  Secondary antibodies, goat anti-mouse 
(IgG)-Alexa Fluor 488 (green fluorochrome), and goat anti-rabbitt (IgG)-Alexa 
Fluor 548 (red fluorochrome) (Molecular Probes) were used as described 
previously (209). Nuclear staining was performed using DAPI. Immunostained Rb 
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and Raf-1 were visualized by confocal microscopy using a Zeiss scanning 
microscope model 510 system equipped with argon (458/488nm) and helium 
neon (543nm) laser systems. 
 
NNK induced Carcinogenesis Animal Model 
  Two experiments were carried out using female A/J mice 4-6 weeks of 
age (Jackson Labs). NNK (NCI) (100mg/kg) was administered to all mice (n=16) 
once a week for 5 weeks. The mice were randomized into two groups; group one 
received the vehicle (PBS) (n=8) and group two received nicotine (n=8) by (i.p.) 
injection at a dose of 1 mg/kg three times a week for an additional 23 weeks. 
Nicotine levels in mice were analyzed using a cotinine ELISA kit. At the end of 
the experiment, the mice were euthanized and the lungs were fixed in 10% 
buffered formalin. The lungs were subsequently examined by stereoscope for 
number of lung tumors. The lungs were paraffin embedded and sectioned for IHC 
staining and pathological examination.  
 
Line1 model of tumor growth and metastasis 
  Line1 Tumor Growth Experiments. Female BALB/c mice age 26-30 
days (Charles River) were clipped and depilated using Nair for complete hair 
removal on the back and flanks. Line1 cells (1 X 106 per tumor) were harvested 
and resuspended in 100l of PBS for injection (252). The mice were randomized 
3-7 days after injection of tumor cells. Mice were separated into two groups 
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Vehicle (n=8) and Nicotine (n=8) (patch or i.p. injection). Mice received nicotine 
by i.p. injection at a dose of 1mg/kg three times a week. Nicotine was also 
applied using transdermal patches (Nico®Derm® CQ, GlaxoSmithKline) at a dose 
of 25 mg/kg daily. Patches (14mg) were cut into 30 equal sized squares 
representing 0.45mg of nicotine using a razor blade. Nicotine was administered 
for 2 weeks and tumor growth was measured thrice weekly. Nicotine levels in 
mice were analyzed using a cotinine ELISA kit. 
 
  Line1 Metastasis Experiments. Line1 cells (1 X 106 per tumor) were 
injected and the mice were subsequently randomized into two groups. Group one 
received the vehicle (n=16) and group two received nicotine (1mg/kg) (n=16) by 
i.p. injection thrice weekly. After 3 weeks of nicotine treatment, the tumors were 
removed under anesthesia and the skin was stapled, mice recovered on a 
warmed heating pad and the staples were removed after 7 days. Mice continued 
to receive nicotine or vehicle for an additional 2 weeks. At the end of the 
experiment, the mice were euthanized and the lungs were fixed in formalin. 
  
Quantitation of Cotinine  
   Level of cotinine in urine was used as a marker for nicotine levels. Urine 
(100l) was collected throughout the length of the experiments and stored in -
20oC for later analysis. Cotinine levels were determined by using the BioQuant 
Cotinine Direct ELISA kit (CalBiotech, Spring Valley, CA) following 
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manufacturer‟s protocols. Nicotine doses used in these studies correlated well 
with cotinine levels in urine of heavy smokers (253,254). Mice receiving 1mg/kg 
nicotine thrice weekly had an average urine cotinine concentration of 3000ng/ml. 
Mice that received 25mg/kg nicotine by transdermal patch had an average 
cotinine concentration of 5000ng/ml cotinine in their urine. Cotinine levels in urine 
are often in a wide range of concentration due to the variance of urine collection 
volumes. In human smokers, cotinine concentrations have been reported in 
values ranging from 1500ng/ml to 8000ng/ml (253-255).  
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Chapter 3: An orally available small molecule disruptor of Rb-Raf-1 
interaction inhibits cell proliferation, angiogenesis and growth of human 
tumor xenografts in nude mice 
 
Abstract 
  Though it is well established that cyclin-dependent kinases phosphorylate 
and inactivate Rb, the Raf-1 kinase physically interacts with Rb and initiates the 
phosphorylation cascade early in the cell cycle.  We have identified an orally-
active small molecule, RRD-251 (Rb – Raf-1 Disruptor 251), that potently and 
selectively disrupts the Rb/Raf-1 but not Rb/E2F, Rb/Prohibitin, Rb/Cyclin E and 
Rb/HDAC binding. The selective inhibition of Rb/Raf-1 binding suppressed the 
ability of Rb to recruit Raf-1 to proliferative promoters and inhibited E2F1-
dependent transcriptional activity.  RRD-251 inhibited anchorage-dependent and 
–independent growth of human cancer cells; and knockdown of Rb with shRNA 
or forced expression of E2F1 rescued from RRD251-mediated growth arrest.  
Oral treatment of mice resulted in significant tumor growth suppression only in 
tumors with functional Rb; and this was accompanied by inhibition of 
angiogenesis, inhibition of proliferation, decreased phospho-Rb levels, and 
inhibition of Rb/Raf-1 but not Rb/E2F1 binding in vivo. Thus, selective targeting 
of Rb-Raf-1 interaction appears to be a promising approach for developing novel 
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anti-cancer agents. 
 
Introduction 
 The retinoblastoma tumor suppressor protein, Rb, is a vital regulator of the 
mammalian cell cycle and its inactivation facilitates S-phase entry (256,257). Rb 
is inactivated through multiple waves of phosphorylation during cell cycle 
progression, mediated by kinases associated with D and E type cyclins in the G1 
phase (20,258). Rb is inactivated in most cancers, either by mutation or deletion 
of the gene, interaction with viral oncoproteins, or alterations in the levels and 
activity of upstream regulators of Rb function (1,38,259,260). Rb controls the 
G1/S boundary by repressing the transcriptional activity of the E2F family of 
transcription factors, especially E2Fs 1, 2, and 3 (30). Many genes necessary for 
DNA synthesis and cell cycle progression, such as cyclins A and E, cdc2, 
thymidylate synthase, DHFR, ORC1 and DNA polymerase  require E2F for their 
expression (49,54,69,124). While cyclins and cdks phosphorylate Rb in mid to 
late G1 phase releasing transcriptionally active E2F (22,23,261), Raf-1 kinase 
binds and phosphorylates Rb early in the G1 phase (173). Disruption of this 
Rb/Raf-1 interaction by an eight amino acid peptide (corresponding to Raf-1 
residues 10-18) prevented Rb phosphorylation even late in the G1 phase, 
suggesting that the binding of Raf-1 is necessary for the eventual inactivation of 
Rb (209). Further, the level of Rb-Raf-1 interaction is elevated in NSCLC tissue 
compared to the adjacent normal tissue (215), suggesting that this interaction 
 72 
contributes to the oncogenesis of these tumors. These observations suggested 
that disruption of the Rb/Raf-1 interaction might have anti-cancer effects and 
raised the possibility that small molecules that can disrupt the Rb/Raf-1 
interaction might be useful as novel anticancer drugs. Here we report a potent 
and selective small-molecule disruptor of Rb/Raf-1 interaction that significantly 
inhibits angiogenesis and tumor growth in vivo in an Rb-dependent manner.   
 
Results 
 
GFGFK, a pentapeptide corresponding to amino acids 13-18 of Raf-1 is 
sufficient for complete disruption of Rb-Raf-1 interaction 
Previous work from our lab had shown that a peptide ISNGFGFK which 
corresponds to amino acids 10-18 on Raf-1 disrupts the Rb-Raf-1 interaction 
(209). In an effort to design peptide-mimics or disruptors of this interaction we 
first performed an alanine scan to determine the minimum requirements for Rb-
Raf-1 disruption. To this end, eight amino acid peptides were synthesized with 
each position replaced with an alanine in the peptide‟s amino acid sequence. The 
eight amino acids synthesized were named A1-A8 corresponding to A for Alanine 
(Figure 12A). Figure 12 shows that amino acids 10, 11 and 12 (I,S or N) are not 
required for Rb-Raf-1 disruption. However, replacement of any amino acids 13-
15 (GFGFK) with alanine was detrimental (Figure 12B). A peptide with the 
sequence FGFK could not disrupt the Rb-Raf-1 interaction indicating that amino 
acid 13 (G) was necessary for complete disruption (Figure 12C). A peptide with 
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the amino acids ISNG also could not inhibit the Rb-Raf-1 binding. Thus, the 
minimum amino acids responsible for Rb-Raf-1 disruption were GFGFK.  This 
peptide could disrupt Rb-Raf-1 as efficiently as the Raf-1 peptide (Figure 12D).  
Although peptides are useful for targeting specific sequences of proteins in vitro 
to disrupt their interactions or enzymatic activity, they are of limited use as drugs 
in vivo. This is because they are degraded very quickly and delivery into cells is 
problematic.  At the same time, information generated from studies on peptides 
can be fruitfully used to generate peptidomimetic drugs or other small molecules 
to target the interaction.  Our future studies will use the GFGFK motif to generate 
new RB-Raf-1 disruptors.  Given that the small peptide could disrupt the binding 
of two relatively large proteins, we embarked on identifying small molecules that 
can disrupt the binding of Raf-1 to Rb.  
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Figure 12. GFGFK pentapeptide is necessary for disruption of the Rb-Raf-1 
interaction. (A) Alanine scan of 8 amino acid Raf-1 peptide. (B) Binding of 35S-
Raf-1 to GST Rb or unprimed GST in the presence or absence of 1µM of the 
peptides. (C) FGFK peptide is not sufficient to disrupt Rb-Raf-1 binding (D) 
GFGFK of the Raf-1 peptide is required for disruption of Rb/Raf-1 binding.  
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Identification of the small molecule Rb-Raf-1 disruptor, RRD-251 
  An ELISA was used to identify compounds that could inhibit the binding of 
GST-Rb to GST-Raf-1. Screening of the NCI diversity library of 1,981 
compounds by Piyali Dasgupta identified two compounds, NSC-35400 and NSC-
35950, which inhibited Rb-Raf-1 interaction 100% and 95% respectively at 20M 
concentration. NSC-35400 and NSC-35950 each contained a benzyl-isothiourea 
derivative and a phenyl-based counter ion (Figure 13A); to establish whether the 
benzyl-isothiourea derivative is the active component, Dr. Nick Lawrence‟s 
laboratory at the Moffitt Cancer Center synthesized RRD-251 (Figure 13A), 
which was similar to NSC-35400 but contains chloride as the counter ion. ELISA 
analysis showed that NSC-35400 could disrupt the Rb-Raf-1 interaction with an 
IC50 of 81 ± 4nM; NSC-35950 had an IC50 of 283 ± 46nM, while RRD-251 had a 
value of 77 ± 3.6 nM (Figure 13B) suggesting that the benzylisothiouronium 
pharmacophore disrupts the Rb-Raf-1 interaction, IC50 assays were done by 
Piyali Dasgupta.   ELISAs showed that the Rb/Raf-1 binding disruptors were 
highly selective for Rb/Raf-1 interaction over Rb/E2F1, Rb/HDAC1, Rb/prohibitin 
(Figure 13C) and Raf-1/Mek (Figure 13D) associations at a concentration of 
20M. 
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Figure 13. Identification of highly specific and selective Rb-Raf-1 inhibitors. (A) 
Chemical structures of compounds identified in the NCI diversity set that showed 
the highest inhibition of Rb-Raf-1 by ELISA. Highest scoring compounds NSC-
35400 and NSC-35950 are both benzyl isothiourea derivatives. RRD-251 was 
synthesized to determine activity based on isothiourea structure. (B) NSC35400, 
NSC35950 and RRD-251 disrupt the Rb-Raf-1 interaction with high potency.  
IC50 values (81nM, 283nM and 77nM, respectively) were determined using 
ELISA.  (C) Rb-Raf-1 inhibitors at 20M concentration do not inhibit other binding 
partners to Rb (E2F1, prohibitin and HDAC1) and to Raf-1 (Mek).  
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RRD-251 inhibits cell proliferation in a wide range of cell lines 
  Since disruption of the Rb-Raf-1 interaction in cells via the Raf-1 peptide 
conjugate was capable of preventing S-phase entry, we evaluated the efficacy of 
RRD-251 to prevent S-phase entry in the A549 NSCLC cell line. RRD-251 could 
inhibit A549 S-phase entry with an IC50 of 15.93M (Figure 14A). It was next 
examined whether RRD-251 could inhibit the proliferation of cells that have 
mutations in the signaling pathways that impinge on Rb function, rather than in 
the Rb gene itself. RRD-251 could inhibit S-phase entry by 50 – 65% in 
pancreatic cancer cell lines such as Aspc1, PANC1, and CAPAN2 that harbor a 
non-functional p16INK4a gene (262) (Figure 14B). RRD-251 also inhibited S-
phase entry in two glioblastoma cell lines U87MG and U251MG, both of which 
are null for p16 and PTEN (263). The metastatic human breast cancer cell line 
MDA-MB-231 harbors a K-Ras mutation and overexpresses EGFR (264); RRD-
251 was able to inhibit its proliferation by 56% (Figure 14B). The A375 
melanoma cell line harbors the V600E B-Raf mutation (265) and RRD-251 
inhibited S-phase entry by 58%. Prostate cell lines LNCaP and PC3 both contain 
mutations in K-Ras and PTEN genes (266), and RRD-251 inhibited proliferation 
86% and 35% respectively (Figure 14B).  These results indicate that treatment 
with RRD-251 could inhibit the proliferation of cell lines harboring a wide array of 
mutations in upstream signaling molecules and cell cycle regulators.   
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Figure 14. RRD-251 inhibits S-phase entry. (A) RRD-251 inhibits A549 S-phase 
entry in BrdU assays with an IC50 of 15.93M. (B) BrdU incorporation assays 
showing the growth arrest mediated by RRD-251 in a variety of tumor cell lines 
harboring various mutations.  RRD-251 could effectively arrest cells with 
mutations in EGFR, p16, PTEN, K-Ras and p53. 
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Inhibition of proliferation by RRD-251 is dependent on Rb status 
  Given the ability of RRD-251 to inhibit Rb phosphorylation, it was 
examined if it could inhibit cell proliferation and whether such an inhibition 
required a functional Rb gene. RRD-251 was effective at inhibiting serum-
induced S-phase entry in parental A549 cells but had no effect on cells stably 
expressing sh6 and sh8, which lacked Rb (Figure 15A). We further examined 
RRD-251 treatment on cancer cell lines containing Rb mutations that render Rb 
non-functional. Osteosarcoma Saos-2 cells that have a loss of Rb (234) were not 
sensitive to treatment with RRD-251 while the U2-OS osteosarcoma cells 
carrying wild type Rb could be inhibited efficiently (Figure 15B). In prostate 
cancer cell lines, RRD-251 was unable to inhibit proliferation in the Rb mutant 
DU145, yet could inhibit 60% of S-phase cells in PC3 cells (wt Rb) (Figure 15B). 
RRD-251 did not inhibit proliferation in the lung cancer cell lines H596 and 
H2172, both of which harbor mutations in Rb, yet treatment with RRD-251 in 
H1650 and H1299 (wt Rb) could inhibit proliferation 90% and 70% respectively 
(Figure 15B).  
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Figure 15. RRD-251 inhibits S-phase entry is dependent on Rb status. (A) A549 
cells stably expressing shRNA to two different Rb constructs display almost 
complete knockdown of Rb protein (B) BrdU incorporation assay showing that 
20M of RRD-251 does not inhibit the proliferation of A549 cells over-expressing 
shRNA constructs to Rb, but arrests wild-type A549 cells and a non-homologous 
(NH) control shRNA. RRD-251 also does not inhibit S-phase entry in cancer cell 
lines that contain mutant Rb. 
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Melanoma and Pancreatic cell lines are sensitive to RRD-251 
Next, the compounds were analyzed for inhibition of cell proliferation in 
several pancreatic cancer and melanoma cells lines, which have elevated MAP 
kinase activity as a result of Ras mutations or B-Raf mutations.  RRD-251 was 
found to have the greatest effect on cell viability in three melanoma cell lines 
(SK-MEL-2, SK-MEL-5, SK-MEL-28) compared to agents that prevent the MAPK 
pathway such as BAY-43-9006 and PD-98089 (Figure 16A-B). These results are 
independent of B-Raf status; SK-MEL-2 contains wild type B-Raf and SK-MEL-5 
and SK-MEL-28 harbor V600E B-Raf mutation. BAY-43-9006 is a multi-kinase 
inhibitor that was found to target B-Raf, Raf-1, Flt-1, C-kit and several other 
receptor tyrosine kinases (RTKs).  In addition, treatment of RRD-251 in 
melanoma cell lines was compared to the standard of care for melanoma 
Dacarbazine (DTIC); melanoma cells were significantly more sensitive to RRD-
251 treatment compared to DTIC (Figure 16C). The aforementioned melanoma 
cell lines were very sensitive to RRD-251 treatment in cell viability assays, this 
increased sensitivity was not observed in other cell lines such as A549 lung 
cancer cell line (data not shown). One surprising finding was that treatment of the 
melanoma cell lines resulted in apoptosis as shown by TUNEL staining (Figure 
17A-B). To confirm these results, PARP cleavage was assessed as a marker for 
apoptosis. SK-MEL-28, and not A549 displayed significant PARP cleavage as 
early as 4 hours from treatment with RRD-251 (Figure 17C).  Again, RRD-251 
was more effective at inducing apoptosis in SK-MEL-28 compared to DTIC as 
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examined by PARP cleavage (Figure 17D), experiments done in Figure 17C-D 
were performed by Sandeep Singh.  
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Figure 16. Melanoma cells are most sensitive to treatment with RRD-251. (A) 
Treatment with RRD-251 at increasing doses (1, 5, 10, 20 and 50µM) inhibits cell 
proliferation in comparison to BAY-43-9006 and PD98089 at the same 
concentrations in two B-Raf V600E mutant cell lines (B) RRD-251 displays 
significant inhibition of cell viability in SK-MEL-2 wild type B-Raf cell line (C) 
RRD-251 has a greater effect on melanoma cells compared to standard of care 
chemotherapy DTIC. 
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Figure 17. RRD-251 induces apoptosis in melanoma cell lines. (A) RRD-251 (20 
M) induces 40% apoptosis as shown by TUNEL assays. (B) Brightfield images 
of TUNEL staining on treated vs. non-treated melanoma cells (C). RRD-251 
induced apoptosis at 4 hours in SK-MEL-28 and not A549 as shown by PARP 
cleavage. (D) RRD-251 induced significantly more apoptosis in SK-MEL-2 and 
SK-MEL-28 compared to DTIC, cisplatin was used as a control. 
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Another cell line found to have increased sensitivity to RRD-251 treatment 
in cell viability assays was the pancreatic cancer cell line, PANC1. We expanded 
this observation by comparing the treatment of RRD-251 on pancreatic cancer 
cell line PANC1 to the immortalized pancreatic ductal epithelial cell line 
HPDE6C7. PANC1 cancer cells were more sensitive to treatment with RRD-251 
than HPDE6C7 (Figure 18A-B). In addition to the cell line comparison, RRD-251 
inhibited cell proliferation more than standard of care chemotherapy for 
pancreatic cancer, Gemcitabine and 5-Fluorouracil (Figure 18A). RRD-251 
treatment was also compared to inhibitors of the Ras/MAPK pathway (BAY-43-
9006 and PD98059) and found to be more effective at inhibiting the cancerous 
PANC1 compared to the immortalized pancreatic ductal cell line HPDE6C7 
(Figure 18B). 
 
Next, we examined the ability of RRD-251 to prevent soft agar colony 
formation. Ability to grow independent of a substratum is a feature of cancer cells 
and growth in soft agar measures the ability of cells to grow in an adherence-
independent manner. Experiments were conducted on a panel of five cell lines to 
assess whether RRD-251 affected their growth in soft agar. Treatment with RRD-
251 (100M) twice a week could significantly inhibit the growth A549, H1650, 
PANC1, SK-MEL-5 and SK-MEL-28 colonies in soft agar (Figure 19).  
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Figure 18. RRD-251 inhibits cell viability in PANC1 cancer cells. (A) RRD 251 
inhibits cell proliferation in PANC1 cells better than standard of care therapy; 5-
Fluorouracil or Gemcitabine (B) Inhibiting Rb-Raf-1 with RRD 251 is more 
effective than the multikinase inhibitor BAY-43-9006 or PD98059. 
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Figure 19. RRD 251 inhibits colony formation in soft agar. RRD 251 (100M) 
dosed thrice weekly inhibits the adherence independent growth in A549, H1650, 
PANC1, SK-MEL-5, and SK-MEL-28 cells.  
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RRD-251 displays high specificity for Rb-Raf-1 interaction 
 
The specificity of RRD-251 for the Rb-Raf-1 interaction in living cancer 
and normal cells was examined by immunoprecipitation-western blot analysis 
(IP-WB). H1650 or HUVEC cells were serum starved for 48 hours and 
subsequently serum stimulated for 2 hours in the presence or absence of RRD-
251 at 100nM, 1M, 5M, 10M and 20M. In the NSCLC H1650 cell line, RRD-
251 inhibited the Rb-Raf-1 interaction with an IC50 of 444nM (Figure20 A-B). In 
the normal HUVEC cell line RRD-251 disrupted Rb-Raf-1 interaction with an IC50 
of 903nM (Figure 20 C-D).  
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Figure 20. RRD-251 specifically targets Rb-Raf-1 interaction in living cells. (A) 
RRD-251 inhibits the Rb-Raf-1 interaction in vivo in H1650 cells. (B) The IC50 for 
disruption in H1650 was 444nM. (C) RRD-251 inhibits the Rb-Raf-1 interaction in 
vivo in HUVEC cells. (D) The IC50 for disruption in HUVEC cells was 903nM. 
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RRD-251 is selective for Rb-Raf-1 interaction 
 
  The selectivity of RRD-251 for Rb-Raf-1 interaction in living cells was next 
examined by IP-WB. A549 cells were serum starved for 72 hours and 
subsequently serum stimulated for 2 hours in the presence or absence of 20M 
of NSC-35400, NSC-35950, and RRD-251; Raf-1 peptide conjugated to 
penetratin (209) was used as a positive control and a Raf-1 scrambled peptide 
was used as a negative control. It was found that the compounds inhibited the 
serum-stimulated binding of Raf-1 to Rb (Figure 21A), but the binding of Rb to 
E2F1 was not affected, experiments done in Figure 21A were performed by Piyali 
Dasgupta.  To further confirm the selectivity of RRD-251, cyclin E was 
immunoprecipitated from lysates of quiescent cells or those serum stimulated for 
8 hours in the presence or absence of RRD-251; western blotting of the 
immunoprecipitates showed that RRD-251 did not inhibit the binding of Rb to 
Cyclin E (Figure 21B). Since B-Raf has been shown to bind to Rb in in vitro pull 
down assays (209) a similar experiment was done on lysates from cells that were 
serum stimulated for 2 hours; RRD-251 did not inhibit the binding of B-Raf to Rb 
(Figure 21C). Similarly, the binding of Raf-1 to Mek1/2 was not affected by RRD-
251 (Figure 21D).  
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Figure 21. RRD-251 is selective for Rb-Raf-1 interaction in living cells. (A) 
Serum-stimulated binding of Raf-1 to Rb is inhibited by Rb-Raf-1 disruptors 
(20µM) as well as a Raf-1 peptide conjugated to penetratin, the drugs do not 
inhibit the binding of E2F1 to Rb.  Further selectivity of the disruption was 
assessed by IP-western blots (B) RRD-251 does not inhibit Rb-Cyclin E 
interaction in cell serum-stimulated for 8 hours. (C) RRD-251 does not disrupt the 
Rb-B-Raf binding in IP-Western Blots.  (D) Treatment of cells with RRD-251 for 5 
minutes in the presence of serum does not affect the binding of MEK1/2 to Raf-1. 
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  Next the ability of RRD-251 to disrupt Rb-Raf-1 interaction in vivo was 
examined by double immunofluorescence experiments in U2-OS cells. Serum 
starved cells display low amounts of Raf-1 (red) in the cytoplasm. However, upon 
serum stimulation for 2 hours, Raf-1 translocates to the nucleus where it binds to 
Rb (green), areas of co-localization can be visualized in yellow. Treatment with 
RRD-251 in the presence of serum displays no evidence of co-localization 
(yellow) (Figure 22). This result verifies that RRD-251 can disrupt the Rb-Raf-1 
interaction in intact cells.  
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Figure 22. RRD 251 can inhibit Rb-Raf-1 colocalization. U2OS cells were 
immunostained with an anti-Raf-1 polyclonal antibody and an anti-Rb mouse 
monoclonal antibody, and the proteins were visualized by confocal microscopy. 
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RRD-251 inhibits Rb phosphorylation independent of kinase inhibition 
  Phosphorylation of Rb is necessary for inactivation of Rb and cell cycle 
progression to occur. Previous studies with the Raf-1 peptide revealed that 
inhibition of Rb-Raf-1 interaction resulted in inhibition of phosphorylation of Rb. 
Examination of lysates from cells serum stimulated for 2 hours (time point when 
Raf-1 binds and phosphorylates Rb) in the presence of RRD-251 showed a 
reduction in Rb phosphorylation, as seen by western blotting (Figure 23A). At 
the same time, in vitro kinase assays showed that RRD-251 did not affect the 
kinase activities associated with Raf-1 (Figure 23B-C) on either MEK or Rb 
substrates, cyclin D on Rb substrate (Figure 23D), or cyclin E on Histone H1 
substrate (Figure 23E), cyclin D and E kinase assays were performed by Piyali 
Dasgupta. These results suggest that the reduction in Rb phosphorylation in cells 
treated with RRD-251 is due to a disruption in the association of Raf-1 with Rb 
and that Raf-1 has to physically interact with Rb to inactivate it.  
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Figure 23. RRD-251 does not affect kinase activity. (A) RRD-251 inhibits Rb 
phosphorylation at the time point when Raf-1 binds to Rb, 2 hours (B-C) RRD-
251 treatment does not inhibit Raf-1 kinase activity on MEK (B) or Rb (C) in in 
vitro kinase assays; BAY-43-9006 was used as a control. (D) RRD-251 does not 
inhibit cyclin D kinase activity in in vitro kinase assays. (E) RRD-251 does not 
inhibit cyclin E kinase activity in in vitro kinase assays.  
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RRD-251 inhibits E2F transcriptional activity 
We next reasoned that if the disruption of the Rb/Raf-1 binding has 
functional consequences on cellular physiology, then RRD-251 should affect the 
transcriptional activity of E2F1. To examine this, transient transfection 
experiments were done in control A549 cells as well as A549 cells stably 
expressing two different shRNA constructs (sh6 and sh8) targeting Rb; these 
A549 cells had significantly less Rb protein compared to parental A549 cells. 
Transfection of E2F1 induced the expression of an E2-CAT reporter; treatment of 
the transfected cells with RRD-251 repressed E2F1-mediated transcription in a 
dose dependent manner (25-100M) in wild type A549 cells but not in the A549 
cells lacking Rb (Figure 24A); this suggests that the presence of Rb is necessary 
for RRD-251 to function, E2-CAT reporter assays done in Figure 24A were done 
by Smitha Pillai. The effect of RRD-251 on the expression of two endogenous 
E2F-regulated proliferative promoters was next examined. A549 cells were 
serum starved for 72 h and serum stimulated for 24h in the presence or absence 
of RRD-251 (20M) and the level of thymidylate synthase (TS) and cdc6 gene 
expression was assessed by Real-time PCR. It was found that inhibition of the 
Rb-Raf-1 interaction correlated with the silencing of the TS and cdc6 genes 
(Figure 24B). We had reported that Raf-1 can be detected on proliferative 
promoters upon serum stimulation and these results indicate that RRD-251 
probably affects E2F-mediated transcription by dissociating Raf-1 from the 
promoters. We had shown that the binding of Raf-1 to Rb resulted in the 
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dissociation of the co-repressor Brg-1 from E2F-responsive proliferative 
promoters (209); chromatin immunoprecipitation assays were carried out to 
examine whether RRD-251 affects this process. It was found that the association 
of Raf-1 to the above promoters upon serum-stimulation for 2 hours was 
disrupted by pre-treatment of cells with RRD-251 (20M) (Figure 24C).  
Furthermore, dissociation of the co-repressor Brg-1 from these promoters was 
also inhibited by RRD-251.  This suggests that RRD-251 can modulate the 
transcriptional regulatory functions of Rb by modulating its phosphorylation status 
and affecting its interaction with chromatin remodeling proteins like Brg-1. The 
association of E2F1, HDAC1 and HP1 with these promoters was not affected by 
RRD-251, as seen by ChIP assays (Figure 24C), ChIP assays done in Figure 
24C were performed by Piyali Dasgupta. 
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Figure 24. RRD-251 Inhibits E2F transcriptional activity (A) RRD-251 inhibits 
E2F1 mediated E2CAT transcription in CAT reporter assays. (B) RRD 251 
inhibits TS and cdc6 gene expression in real-time PCR experiments. (C) ChIP 
assays show that Brg1, not Raf-1 is present on quiescent A549 cdc6, cdc25A, 
and TS promoters. Upon serum stimulation, Brg1 dissociates from the promoters, 
correlating with Raf-1 binding. Serum stimulation in the presence of RRD-251 
causes the dissociation of Raf and retention of Brg1 on E2F1 responsive 
promoters. Serum stimulation for 16 hours causes dissociation of Rb, Raf-1, 
Brg1, HDAC1 and HP1 from the promoters. An irrelevant antibody was used as a 
control for immunoprecipitations; c-fos promoter was used as a negative control. 
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RRD-251 inhibits angiogenesis in vitro and in vivo 
  Raf-1 kinase has been shown to play a role in facilitating angiogenesis 
(210,267) and it has been suggested that Raf-1-mediated inactivation of Rb is 
involved in the process (209). We first examined A549 cells treated with RRD-
251 for VEGF levels in culture media. Asynchronously growing A549 cells treated 
with RRD-251 for 24hours with either 20M or 50M displayed a significant 
decrease in VEGF levels (Figure 25A). To examine whether angiogenic tubule 
formation could be inhibited by RRD-251, human umbilical vein endothelial cells 
(HUVECs) were grown in matrigel in the presence or absence of 20M RRD-251; 
RRD-251 significantly inhibited the angiogenic tubule formation (Figure 25B). 
These results were confirmed in an ex-vivo experiment using rat aortic rings. As 
shown in Figure 25C, 20M RRD-251 was able to inhibit angiogenic sprouting 
from rat aortic rings grown in growth factor rich matrigel for 7 days. Quantitation 
of vessel area showed a significant reduction in angiogenesis (Figure 25D). 
Because RRD-251 was able to greatly inhibit angiogenesis in vitro, we examined 
whether RRD-251 could inhibit angiogenesis in matrigel plugs in vivo (251). 
Aythmic nude mice were injected with cold matrigel in both flanks. Mice were 
administered either vehicle or RRD-251 50 mg/kg body weight (MPK) by 
intraperitoneal (i.p.) injection daily for one week. On the last day the mice were 
injected with 100 MPK FITC-Dextran via the tail vein. The mice were euthanized 
and matrigel plugs were fixed in formalin; angiogenesis in the entire plugs were 
assessed by confocal imaging. FITC images displayed growth of angiogenic 
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tubules in plugs from mice that received vehicle; in contrast, there was a 
remarkable inhibition of angiogenic vessel formation in the matrigel plugs from 
mice treated with RRD-251 (Figure 25E). Quantitation of vessel intensity is 
plotted as relative angiogenesis per image and shows significant inhibition, 
p=0.0004 (Figure 25F). Further examination of the matrigel plugs by H&E 
staining showed a complete inhibition of cells migrating into the matrigel for 
vessel formation (Figure 25G). 
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Figure 25. RRD-251 inhibits angiogenesis in vitro and in vivo. (A) RRD-251 
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inhibits VEGF levels in asynchronously growing A549 cells when treated at 20M 
and 50M. (B) RRD-251 inhibits Human Umbilical Vein Endothelial cell 
angiogenic tubule formation in matrigel. (C) RRD-251 inhibits angiogenesis in a 
rat aorta matrigel model. (D) Quantitation of vessel density. (E) Confocal FITC 
images of matrigel plugs from nude mice treated with Vehicle or RRD-251 50 
MPK daily for one week. (F) Quantitation of FITC vessels in plugs. (G) H&E 
staining of matrigel plugs from nude mice treated with Vehicle or RRD-251 50 
MPK. H&E images display ¼ of matrigel plug. 
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Antitumor activity of RRD-251 
The ability of RRD-251 to inhibit cell proliferation, adherence-independent 
growth and angiogenesis demonstrates that it has desirable anti-cancer drug 
properties.  This prompted us to assess whether RRD-251 could inhibit tumor 
growth in vivo in nude mouse xenograft models. Athymic nude mice were 
implanted s.c. with 1X107 A549 cells bilaterally and the tumors were allowed to 
reach 200mm3 in size before oral or i.p. administration of RRD-251 or vehicle 
(209,248). Tumors from vehicle treated mice grew to an average size of 1040 
±128 mm3; in contrast, tumors in mice treated with RRD-251 did not grow and 
even regressed slightly (50 MPK-i.p.: 145 ± 20mm3; 150 MPK-oral 148 ±32 mm3) 
(Figure 26A). Oral dose response experiments were carried out on A549 
xenografts, which resulted in RRD-251 100 MPK and 150 MPK completely 
inhibiting tumor growth (Figure 26B). Tumors from vehicle treated mice reached 
an average size of 996 ± 180 mm3; in contrast, tumors in mice treated with RRD-
251 (oral) responded in a dose dependent manner. Complete inhibition was seen 
in 100 MPK-oral: 293 ± 44mm3 and 150 MPK-oral: 237 ± 67 mm3 (Figure 26B). 
A549 xenograft assays in Figure 26A-B were done by Adam Carie. Similar 
results were observed with H1650 xenograft tumors; RRD-251 inhibited tumor 
growth significantly  (2185 ± 326mm3 in vehicle treated animals compared to 557 
± 76mm3 in RRD-251 (50 MPK-i.p.) treated animals) (Figure 26C). We also 
examined the efficacy of RRD-251 treatment in SK-MEL-28/matrigel xenografts 
since this cell line was most sensitive to treatment with RRD-251. SK-MEL-28 
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cells do not form tumors easily in mice and therefore were used in combination 
with matrigel (1:1) to allow the tumors to form. Mice treated with RRD-251 50 
MPK-i.p. had significantly smaller tumors compared to vehicle treated mice 
(861±106mm3 in vehicle treated mice compared to 341±42mm3 in RRD-251 
treated mice) (Figure 26D). These results indicate that disruption of Rb-Raf-1 
interaction is a viable method for inhibiting several types of tumors.  
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Figure 26.  Intraperitoneal (i.p.) and oral administration of RRD-251 inhibits 
human tumor growth in nude mice. (A) A549 cells xenotransplanted bilaterally 
into the flanks of athymic nude mice were allowed to grow for 14 days until tumor 
volume reached 200mm3; daily administration of RRD-251 at 50 MPK-i.p. and 
150 MPK-oral completely inhibited tumor growth. (B) Dose response of RRD-251 
administered by oral gavage, 100 MPK and 150 MPK could completely inhibit 
tumor growth.  (C) RRD-251 inhibited H1650 xenograft tumor growth in nude 
mice. (D) RRD-251 inhibited SK-MEL-28 melanoma xenograft tumor growth in 
nude mice. 
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  The A549 tumors (Figure 27A) were harvested at the end of the treatment 
and analyzed by immunohistochemistry by staining with hematoxylin and eosin 
(H&E), Ki-67, phospho-Rb (807,811), and CD-3, IHC staining was performed by 
Sandy Livingston in the University of South Florida IHC core.  Histopathological 
analysis revealed a significant inhibition of proliferation in tumors from RRD-251 
treated animals as seen by a reduction in Ki-67 staining (Figure 27A); 
phosphorylation of Rb was also reduced as seen by staining with an antibody to 
phospho-Rb (Figure 27A). The tumors also showed a reduction in 
microvasculature, as seen by CD31 staining (Figure 27A). Quantitation of Ki-67 
staining, phospho-Rb staining and CD31 staining is shown (Figure 27 B-D). To 
assess whether RRD-251 reached its target, tumors were homogenized and 
lysates were prepared to assess the inhibition of Rb-Raf-1 interaction in vivo. 
RRD-251 was found to specifically inhibit Rb-Raf-1 but not Rb/E2F1 binding in 
the lysates from tumor xenografts of treated mice (Figure 28). 
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Figure 27. Tumors treated with RRD-251 display a decrease in proliferative and 
angiogenic markers (A) Immunohistochemical staining of tumors from mice 
treated with RRD-251. Tumors were stained with Ki-67 for proliferation, pRb for 
cell cycle, and CD31 for angiogenesis. (B-D) Quantitation of staining intensity for 
Ki-67, pRb and CD31. 
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Figure 28. RRD-251 disrupts Rb-Raf-1 binding in xenograft tumors. Both doses 
of RRD-251 inhibit the Rb-Raf-1 interaction in tumor lysates without inhibiting Rb-
E2F1 interaction, as seen by IP-Western blots. 
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Tumor Growth Inhibition by RRD-251 is Rb-dependent 
 
Since RRD-251 did not inhibit the proliferation of A549 cells lacking Rb in 
vitro, experiments were done to assess whether tumors generated from these 
cells can respond to RRD-251 in vivo. Experiments in Figure 29A were carried 
out on nude mice carrying tumors from A549 cells stably expressing shRNAs for 
Rb (sh6 and sh8). Interestingly, these tumors did not respond to RRD-251 and 
continued to grow at the rate of the vehicle treated tumors (Figure 29 A-B) A549-
sh6 and sh8 xenograft assays in Figure 29A-B were performed by Adam Carie 
and repeated by Rebecca Kinkade. To examine whether the sh6 and sh8 tumors 
maintained downregulation of Rb, lysates were made from the sh6 and sh8 
tumors at the end of the experiment and a western blot was done for Rb. It was 
found that these tumors lacked Rb, further confirming that RRD-251 specifically 
targets the Rb-Raf-1 protein interaction to inhibit cell proliferation and tumor 
growth (Figure 29C). 
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Figure 29. Inhibition of tumor growth is dependent on a functional Rb protein. 
A549-sh6 and A549-sh8 cells were implanted into the flanks of nude mice. (A-B) 
RRD-251 was unable to inhibit tumor growth in tumors lacking Rb protein. (C) 
Tumors maintain downregulation of Rb protein at the end of the experiment. 
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Discussion 
 
    The Ras/Raf/Mek/MAPK cascade is a proliferative pathway induced by a 
wide array of growth factors and is activated in many human tumors 
(175,176,268) and is an attractive target for the development of anti-cancer drugs 
(207,208,210,267). Raf-1 kinase itself has been targeted for cancer therapy and 
two clinical attempts have been made to inhibit Raf-1 activity in patients 
(190,269,270). It has been shown that signaling pathways through the MAP 
kinase cascade do not proceed in a linear fashion; instead they have been found 
to have substrates outside the cascade as well (173,271,272). In this context, the 
Rb protein appears to be an important cellular target of the Raf-1 kinase outside 
the MAP kinase cascade. Analysis of human NSCLC tumor samples revealed 
elevated levels of Rb-Raf-1 binding in tumor compared to adjacent normal 
controls (215), suggesting that Rb-Raf-1 interaction contributes to the 
oncogenesis of these tumors. While it is established that Rb gene itself is 
mutated in cancers like retinoblastoma, osteosarcoma and small-cell lung 
carcinoma, the majority of tumors harbor mutations in the upstream regulators of 
Rb function (1,38). These include genes like Ras, PTEN, p16INK4 as well as 
receptor tyrosine kinases (273-275). Our results show that the disruption of the 
Rb-Raf-1 interaction can be fruitfully utilized to inhibit the proliferation of cells 
harboring such mutations in the Rb regulatory pathway.  Thus we believe that 
these molecules have the potential to target a wide variety of human cancers.  
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  While inhibitors of cell proliferation, DNA damaging agents as well as 
microtubule disruptors have widely been used as anticancer agents, 
developments in the past decade have demonstrated that targeting angiogenesis 
is also an effective way of combating tumor growth (210). Thus humanized 
antibodies have been approved for use against certain cancers; further, recent 
studies suggest that growth factors like PlGF might be potential targets for anti-
angiogenic therapy (276). In this context, our results show that RRD-251 can not 
only inhibit cell proliferation, but also inhibit neoangiogenesis in vitro and in vivo.  
Given the published reports that Raf-1 kinase contributes to angiogenesis and 
that VEGF can induce Rb phosphorylation, it is likely that RRD-251 is inhibiting 
angiogenesis by affecting these molecules (210,277).  The ability of RRD-251 to 
inhibit both cell proliferation as well as angiogenesis might be acting in a two-
pronged manner to inhibit the growth of tumors in vivo; these are desirable 
features in anti-cancer drugs.   
 
  Raf-1 has been shown to play a role in apoptosis, independently of MAPK 
activation. Raf-1 has prosurvival functions that regulate apoptosis; two different 
mechanisms have been established for this role (195,278).  In one study, Raf-1 is 
targeted to the mitochondria by Bcl-2 protein promoting resistance to apoptosis 
(195). Another anti-apoptotic mechanism in which Raf-1 was shown to function 
was through its association with apoptosis signal regulating kinase 1 (ASK1) 
(278). It can be imagined that our results with apoptosis in melanoma cells may 
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be reflective of one of these two scenarios. ASK1 also binds to Rb to inactivate it 
so that it can overcome Rb‟s restraint on the cell cycle and therefore induce 
apoptosis (237). Since both Raf-1 and Rb bind to ASK1, it is possible that in 
certain types of cells (melanoma) these proteins function in an oligomeric 
complex where Raf-1 is bound to Rb and ASK1, when the Rb-Raf-1 interaction is 
disrupted, ASK1 can then induce apoptosis. Further studies are needed to 
examine the cell line and stimuli dependency of this interaction and will be useful 
for developing novel inhibitors capable of either inducing apoptosis or inhibiting 
cell proliferation, depending on the cellular context. 
 
  While it has been difficult to generate small molecule inhibitors of 
protein-protein (269) interactions that are clinically active, recent success in 
disrupting the hdm2-p53 (279) interaction shows that this is a viable strategy to 
develop novel anti-cancer drugs. Identification of RRD-251 as a cell–permeable, 
orally available, and highly selective inhibitor of the Rb-Raf-1 interaction is an 
example of the practicality of targeting protein-protein interaction for cancer 
therapy. Although we find that RRD-251 inhibits Rb-Raf-1 in vitro at nM 
concentrations in an in vitro ELISA assay, higher concentrations are needed to 
inhibit cell proliferation as well as growth of cells in soft agar; this finding is similar 
to what has been observed with other anti-cancer drugs such as BAY-43-9006, 
R547, and Iressa (212,280,281). At the same time, our in vivo studies show that 
concentrations can be achieved in vivo where RRD-251 has a significant 
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therapeutic benefit.  
 The finding that RRD-251 is effective in inhibiting the proliferation of cells 
harboring a wide variety of mutations in signaling cascades that inactivate Rb, 
but does not affect cells carrying mutated Rb or no Rb shows the specificity of 
this agent. Rb protein has been reported to interact with about one hundred 
proteins in the cell; it can be imagined that small molecules that can maintain the 
tumor suppressor functions of Rb by disrupting its physical interaction with other 
proteins would be a fruitful avenue to develop novel anti-cancer drugs.  
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Chapter 4: Nicotine Promotes Tumor Growth and Metastasis in Mouse 
Models of Lung Cancer 
 
Abstract 
Nicotine is the major addictive component of tobacco smoke. Although it is 
non-carcinogenic, it can induce cell proliferation and angiogenesis in non-
neuronal cells. Here we show that nicotine significantly promotes the progression 
and metastasis of tumors already initiated. Nicotine administration either by 
intraperitoneal (i.p.) injection or transdermal patches caused a remarkable 
increase in the size of Line1 tumors implanted into BALB/c mice. Once the 
tumors were surgically removed, nicotine treated mice had markedly higher 
tumor recurrence as compared to the vehicle treated mice (59.7 % +/- 3.5 vs. 
19.5 % +/- 7.7 respectively, p = 0.01, n=16). Nicotine also increased metastasis 
of dorsally implanted Line1 tumors to the lungs. While vehicle treated mice had 
an average of 0.9 +/- 0.2 lung metastases per mouse, nicotine treated mice had 
8.1 +/- 1.7, p = 0.001, n=16. These studies on transplanted tumors were 
extended to a mouse model where the tumors were induced by the tobacco 
carcinogen, NNK. Lung tumors were initiated in A/J mice by i.p. injection of NNK; 
administration of 1 mg/kg nicotine three times a week led to an increase in the 
size as well as the number of tumors formed in the lungs. In addition, nicotine 
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significantly reduced the expression of epithelial markers, E-Cadherin and -
Catenin in the tumors of A/J mice. We believe that exposure to nicotine, either by 
tobacco smoke or nicotine supplements might facilitate increased tumor growth 
and metastasis. 
 
Introduction 
Lung cancer is the predominant cancer in the developed world and its 
onset is strongly associated with smoking habits (282,283). Despite the evident 
linkage of smoking to lung cancer, 30% of smokers diagnosed with lung cancer 
continue to smoke (284). Tobacco smoke contains a wide array of compounds 
that are deleterious to health; some of these compounds such as 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N‟-nitrosonornicotine 
(NNN) are nicotine derivatives and are highly carcinogenic (218). These 
molecules can form adducts with cellular DNA, leading to mutations in vital genes 
like Ras, p53, and Rb (219). While nicotine is the addictive component in 
cigarette smoke, it is not a carcinogen and cannot initiate tumor formation in 
animals.  
 
Nicotine exerts its cellular functions through nicotinic acetylcholine 
receptors (nAChRs), which are widespread in neurons and neuromuscular 
junctions (285).  nAChRs are pentameric proteins consisting of nine  subunits 
(2-10) and three  subunits (2-4) in non-neuronal cells; delta and  subunits 
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are present in neuronal systems (220). Recent studies have shown that nAChRs 
are also present in a wide array of non-neuronal tissues, including human 
bronchial epithelial cells, human endothelial cells and astrocytes (220-222). The 
finding that nAChRs are present on non-neuronal cells was followed by the 
observation that nicotine could induce the proliferation of endothelial cells (221) 
as well as lung carcinoma cell lines (226). In non-neuronal tissues, nicotine has 
been shown to induce the secretion of growth factors such as bFGF, TGF-, 
VEGF, and PDGF (286). Nicotine has been shown to induce migration and 
invasion of cells via phosphorylation of calpain family members (287). Nicotine 
and its related carcinogens, like NNK, have been found to activate Raf-1, EGFR, 
Src, Akt and 5-lipooxygenase-mediated growth stimulatory pathways 
(227,288,289). 
 
In addition, nicotine has also been found to inhibit apoptosis induced by 
opioids, etoposide, cisplatin, and UV irradiation in lung cancer cells (290,291). 
Nicotine‟s inhibitory effects have been attributed to its ability to activate and 
phosphorylate anti-apoptotic proteins like Bcl-2, induction of NF-κB complexes, 
activation of Akt pathway as well as inactivation of pro-apoptotic proteins such as 
Bad and Bax through phosphorylation in lung cancer cells (292,293). It was 
found that nicotine could prevent the apoptotic activity of gemcitabine, cisplatin 
and taxol, which are standard therapy for NSCLC, in a variety of human NSCLC 
cell lines. The protective effects of nicotine involved induction of IAP proteins, 
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XIAP and survivin in lung cancer cells (290). The anti-apoptotic effects of nicotine 
were mediated by activation of Akt which facilitated the stabilization of XIAP 
proteins and transcriptional activation of survivin. Nicotine stimulation increased 
the binding of E2F1 to the survivin promoter (290). These results further support 
clinical studies that demonstrate how patients who continue to smoke have 
worse survival profiles than those who quit before treatment (282). These studies 
also raise the possibility that patients who use nicotine supplements for smoking 
cessation might reduce the response to chemotherapeutic agents. 
 
Recently, the mechanisms underlying the proliferative signaling of 
nAChRs have been discovered. It was found that nicotine functions like a growth 
factor, binding to nAChRs causing a recruitment of β-arrestin and Src to the 
nicotinic receptors resulting in the activation of MAPK and the subsequent 
binding of Rb-Raf-1 pathways (215). It was found that the levels of Rb-Raf-1 
interaction were elevated in human NSCLC tumors compared to normal adjacent 
tissue (215) (Figure 30A). This result suggested that Rb-Raf-1 pathways 
probably contribute to oncogenesis; the increased presence of Raf-1 on 
proliferative promoters in human NSCLC tumors supports this hypothesis (215) 
(Figure 30B). It is likely that tumors exposed to nicotine have a proliferative 
advantage. Smokers have been found to be less responsive to chemotherapy 
and were also found to have increased metastasis of breast cancers to the lung 
(294-296). 
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Figure 30.  Rb-Raf-1 interaction is elevated in tumors. (A) NSCLC tumors (T) 
contained more Rb-Raf-1 complexes than adjacent normal tissue (N). Rb-Raf-1 
interaction was assessed by IP-WB on nuclear extracts. (B) ChIP assays on 
human NSCLC tumor samples show that more Raf-1 was present on cdc6 and 
cdc25A promoters in tumor samples compared to normal adjacent tissues. 
Adapted with permission from Dasgupta et al (215). 
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The key players mediating the mitogenic effects of nicotine are -arrestin-
1 and Src kinase. Src family kinases are involved in multiple receptor-mediated 
signaling pathways that regulate proliferation, survival, metastasis and 
angiogenesis. -arrestin-1 is vital for nicotine mediated activation of Src and cell 
proliferation. -arrestin-1 family members have been shown to act as scaffold 
proteins that recruit a variety of signaling molecules to membrane-bound 
receptors in a highly coordinated manner. -arrestin-1 is required for nAChR-
mediated activation of MEK/ERK pathway and proliferation of NSCLCs. Binding 
of nicotine to nAChRs causes a recruitment of -arrestin-1 and Src to the 
nicotinic receptor resulting in activation of Rb-Raf-1 pathways (297). This 
signaling event causes the recruitment of E2F1, Raf-1 and Rb on E2F responsive 
proliferative promoters (215). Raf-1 inactivates Rb and facilitates Rb dissociation 
from the promoters and an increase in E2F1 therefore, inducing transcription of 
S-phase genes and further cell cycle progression (215). Understanding of the 
signaling pathways mediated by nAChRs in cancer cells may be a possible 
avenue for cancer therapy by targeting either -arrestin-Src or Rb-Raf-1 
interactions (Figure 31). We have shown in Chapter 3 that inhibition of Rb-Raf-1 
interaction is a viable mechanism for targeted cancer therapy. 
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Figure 31.  Schematic predicting the proliferative signaling by nAChRs in NSCLC 
cells. Nicotine stimulation causes the assembly of oligomeric complexes 
involving -Arrestin, Src and nAChRs, facilitating the activation of Src.  This leads 
to the activation of Raf-1, which binds to Rb; activation of MAPK and cyclins/cdks 
also occur. The activation of Src facilitates the binding of Raf-1 to Rb and 
multimeric complexes containing Rb, Raf-1 and E2F1 occupy proliferative 
promoters. Sustained mitogenic signaling leads to the dissociation of Raf-1 and 
Rb, while E2F remains bound to the promoter facilitating S-phase entry. 
Disruption of the Rb-Raf-1 interaction can block nicotine induced proliferation of 
NSCLC cells. Adapted with permission from Dasgupta et al (215). 
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Induction of cell proliferation, enhancement of cell survival and induction of 
angiogenesis are all effects seen from nicotine stimulation and they all contribute 
to the growth and progression of solid tumors in vivo. Studies from the Cooke 
laboratory have shown that nicotine can induce angiogenesis both in vitro and in 
vivo (222,223). It has also been shown that second hand smoke could induce 
tumor angiogenesis and growth (298). Nicotine induces angiogenesis through α7 
nAChR subunits. Interestingly, inhibition of Src or Rb-Raf-1 interaction and not 
PI3K could efficiently inhibit nicotine induced angiogenesis (297). 
 
Although tobacco carcinogens initiate and promote tumorigenesis, recent 
studies on nicotine raise the possibility that exposure to nicotine either by 
cigarette substitutes or nicotine supplements might confer a proliferative 
advantage for tumors already initiated. Recent studies from the Russo lab has 
shown that inhibition of nAChRs by -cobratoxin can inhibit the growth of A549 
tumors in immunocompromised mice (229); similarly, it has been shown that a 
combination of nicotine and estradiol can promote the growth of A549 tumors in 
athymic mice (230). While these studies suggest a role for nAChRs in tumor 
growth, there are no studies demonstrating the effect of nicotine as a single 
agent on tumor growth and metastasis in immunocompetent mice. Studies 
presented here show that nicotine by itself can induce the growth and metastasis 
of tumors in immunocompetent mice, independent of other tobacco carcinogens. 
Nicotine administered intraperitoneally or by commercially available transdermal 
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patches could promote tumor growth substantially.  Further, mice exposed to 
nicotine showed significantly enhanced lung metastasis as well as tumor 
recurrence post surgical removal of the primary tumor. Similar effects were 
observed on implanted tumors as well as tumors induced by the tobacco 
carcinogen, NNK.   These results imply that nicotine can enhance the growth and 
metastasis of pre-established lung tumors.  
 
Results 
Nicotine promotes the growth of tumors in mice 
To determine the effects of nicotine on tumor growth and metastasis in 
immunocompetent mice, Line1 mouse adenocarcinoma cells were utilized. Line1 
cells form subcutaneous (s.c.) tumors in BALB/c mice, which can metastasize to 
the lungs (252). To examine whether nicotine induced proliferation of Line 1 cells, 
the cells were serum starved for 72 hours and subsequently stimulated with 1µM 
nicotine for 18 hours. S-phase entry was measured using BrdU incorporation 
assays. Nicotine could efficiently stimulate Line1 cells into S-phase and 
treatment with the Rb-Raf-1 disruptor, RRD-251 abrogated nicotine induced 
proliferation in Line1 cells (Figure 32).  Next, it was examined how nicotine 
affects the growth and metastasis of Line1 cells implanted into the flanks of 
BALB/c mice (Figure 33). Female BALB/c mice were injected with 1 million Line1 
cells s.c. into each flank. The mice were randomized into two groups, with one 
group receiving vehicle (n=8) and the second receiving 1mg/kg nicotine (n=8) 
thrice weekly by intraperitoneal (i.p.) injection (Figure 33).  
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Figure 32. Nicotine (1M) stimulates S-phase entry in Line1 mouse 
adenocarcinoma cells. Treatment with RRD-251 (20M) abrogated nicotine-
induced proliferation in Line1 cells.  
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Figure 33.  Schematic for the experimental design of Line1 tumor growth and 
metastasis in BALB/c mice.  Line1 cells (1x106) are injected s.c. into the flanks of 
shaved BALB/c mice. Mice are randomized into two groups and administered 
either Vehicle (PBS) or nicotine 1mg/kg thrice weekly for 2 weeks. After two 
weeks, or when tumors reach 500-700mm3, the tumors are surgically removed 
and the skin is stapled for one week. Mice continue to receive treatment for 
another 2 weeks or until tumors recurrence is evident. 
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Mice that received nicotine had significantly larger tumors compared to 
those receiving vehicle; tumor volumes averaged 695 +/- 98 mm3 in vehicle 
treated mice, compared to 2267 +/- 369 mm3 in nicotine treated mice (Figure 
34A) p = 0.002. Based on the results with nicotine administered i.p., experiments 
were done to examine whether nicotine administered by over-the-counter 
transdermal patches could promote tumor growth. BALB/c mice (n=16) implanted 
with Line 1 tumors were randomized into two groups and nicotine patches were 
applied daily at a dose of 25 mg/kg nicotine. It was found that nicotine 
administered by transdermal patches could significantly increase the growth of 
Line1 tumors; control mice had an average tumor volume of 530 +/- 59 mm3 
whilst nicotine patch mice had an average volume of 871 +/- 106 mm3 (Figure 
34B), p=0.019. Mice wearing nicotine patches also displayed changes in tumor 
shape, from oval with well-defined borders, to polygonal with irregular borders 
(Figure 34C), potentially suggesting the nicotine treatment confers a more 
malignant phenotype. These experiments confirm that exposure to nicotine, even 
through nicotine supplements, might affect pre-established tumors.  
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Figure 34. Nicotine promotes Line1 tumor growth. (A) Nicotine (1mg/kg) 
significantly promotes the growth of s.c. Line1 tumors when administered thrice 
weekly by i.p. injection. (B) Daily application of nicotine transdermal patches (25 
mg/kg) enhanced tumor growth. (C) Mice bearing nicotine patches displayed 
irregular polygonal shaped tumors compared to control mice. 
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Nicotine promotes re-growth and metastasis of tumors in mice 
  Since nicotine was found to enhance tumor growth, experiments were 
conducted to assess its effect on tumor metastasis.  In order to examine this, the 
implanted tumors were surgically removed after 14 days of treatment or once 
they reached 500-700mm3. Tumors were removed to prevent discomfort from 
large tumors. Mice were anesthetized for tumor removal, and wounds were 
stapled closed. After the removal of staples, mice were administered vehicle or 
nicotine by i.p. injection for an additional 14 days. Interestingly, mice treated with 
nicotine showed a higher rate of tumor recurrence after the tumors were 
surgically removed (Figure 35A); vehicle treated mice displayed an average of 
19 +/-7% tumor recurrence, as compared to an average of 59 +/- 3% tumor 
recurrence in nicotine (1mg/kg) treated mice, p= 0.01. Tumor recurrence was 
calculated as percentage of recurring tumors out of the total number of tumors 
removed. Mice receiving the vehicle had an average of 0.9 +/- 0.2 metastatic foci 
in the lungs per mouse; in comparison, mice that received nicotine, 1 mg/kg 
thrice weekly, had an average of 8.1 +/- 1.7 foci in the lungs per mouse, p=0.001 
(Figure 35B). As shown in Figure 35C, nicotine treated mice also displayed 
significantly greater number of lung metastases as well as larger metastatic foci 
compared to those receiving vehicle. In addition, histologic examination of the 
lung tumors revealed larger metastatic foci in the nicotine treated mice (Figure 
35D). 
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Figure 35. Nicotine increases metastatic potential. (A) Nicotine treated mice 
(1mg/kg) displayed higher incidence of tumor recurrence following surgical 
removal of tumors compared to the vehicle control group p=0.01, n=16. (B) 
Graph displaying the average total number of lung tumors per mouse in vehicle 
and nicotine treated mice, p=0.001, n=16. (C) Nicotine treated mice display 
significantly more lung metastasis from primary Line1 subcutaneous (s.c.) 
tumors. (D) H&E staining of lungs from vehicle and nicotine treated mice, nicotine 
treated mice display larger tumors. 
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Nicotine enhances the growth of tumors induced by tobacco carcinogens 
Experiments were designed to examine the effects of nicotine on tumors 
induced by the tobacco carcinogen, NNK; this experimental system mimics a 
situation where tumors are initiated by a carcinogen, followed by exposure to 
nicotine alone. Towards this purpose, A/J mice (n=16) were treated with 
100mg/kg NNK once a week for five weeks to initiate tumor formation and 
subsequently they were randomized into two groups. One group of mice received 
the vehicle (PBS) (n=8) whilst the second group received nicotine 1mg/kg (n=8) 
thrice weekly by i.p. injection; mice were treated with nicotine or vehicle for 28 
weeks (Figure 36). At necropsy, lungs from both vehicle and nicotine-treated 
mice had tumors (Figure 37A-B). H&E stained lung sections, from both groups, 
were scanned and a pathologist (Dr. Domenico Coppola, Moffitt Cancer Center 
Pathology) outlined the tumor. The size and number of tumor foci were 
quantitated. Mice that received PBS after NNK injections had an average of 10 
+/- 3 lung tumors per section and mice that received nicotine 1mg/kg had 16 +/- 3 
tumors per section (Figure 37C), p =0.01. Tumor size was also increased in 
nicotine treated mice (Figure 37D). This suggests that exposure to nicotine of 
pre-established tumors can result in enhanced tumor growth. 
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Figure 36. Schematic for NNK induced carcinogenesis experimental design. A/J 
mice were administered 100 mg/kg NNK once a week for 5 weeks and 
subsequently randomized into two groups. The control group received the vehicle 
(PBS) thrice weekly and group two received nicotine 1mg/kg thrice weekly by i.p. 
injection. Treatment with nicotine or PBS continued for 28 weeks. At endpoint, 
mice were sacrificed and lungs were examined for tumors. 
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Figure 37.  Nicotine (1 mg/kg) increases number and size of NNK induced lung 
tumors. (A) H&E staining of transverse sectioning of lungs. (B) Representative 
scanned images of H&E stained coronal lung sections. (C) Nicotine increases the 
average number of lung tumors per mouse p=0.01, n=8. (D) Nicotine increased 
tumor area. 
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Nicotine facilitates EMT-like changes in lung cancers 
Given the observation that nicotine can induce tumor growth and promote 
metastasis, attempts were made to understand the molecular events mediating 
these processes.  Epithelial-mesenchymal transition (EMT) is a phenomenon by 
which cells lose their epithelial phenotype and acquire more mesenchymal 
features that facilitate detachment and migration.  We examined the tumors in 
A/J mice for changes consistent with an EMT-like phenomenon, using 
immunohistochemical staining for E-cadherin and -Catenin, two proteins 
involved in the adhesion of epithelial cells. -Catenin binds to E-Cadherin to 
facilitate cell adhesion and to exert its signaling functions. E-cadherin levels were 
found to be significantly decreased in the tumors of mice treated with nicotine 
(Figure 38A), E-Cadherin staining was performed by Sarmistha Banerjee; the 
results are quantified in Figure 38B. The same mice revealed a loss of the 
typical -Catenin membranous staining pattern in their lung tumors (Figure 38C), 
β-Catenin staining was performed by Sandy Livingston in the USF IHC core; the 
results are quantitated in Figure 38D. 
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Figure 38. Nicotine reduced expression of epithelial markers. (A) E-cadherin 
staining of A/J lung tumors induced by NNK or NNK+ Nicotine. (B) Quantitation of 
E-cadherin intensity in tumors. (C) -Catenin staining of A/J lung tumors induced 
by NNK or NNK and nicotine. (D) Quantitation of membranous -Catenin. 
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Discussion 
 Several observations suggest that those exposed to tobacco carcinogens 
are more likely to develop larger, more vascularized tumors with a high 
propensity for metastatic spread and resistance to chemotherapy (296).  In 
addition, about 30% of lung cancer patients who are smokers continue to smoke 
after they have been diagnosed (282). This is problematic, as smokers who 
continue to use tobacco after a cancer diagnosis or return to smoking, 
experience increased adverse medical consequences, such as: increased tumor 
progression, development of a second cancer, greater recurrence following 
successful treatment, greater cancer-related mortality, and reduced quality of life  
(299,300).  While these studies strongly demonstrate a role for tobacco 
carcinogens in the initiation, growth and progression of cancers, the relative 
contribution of nicotine by itself to these processes is not known.  This is a 
significant aspect, since the use of nicotine supplements is usually part of most 
cigarette smoking cessation programs. Nicotine supplementation through 
patches, nasal sprays, chewing gum, etc., is now widely used to assist in 
smoking cessation. The serum concentrations of nicotine achieved with these 
modalities vary, but the transdermal delivery of nicotine can result in serum 
concentrations of nicotine that are observed in active smokers (301). Although it 
is known that nicotine is not carcinogenic, the risks associated with long-term 
nicotine supplementation are unknown. 
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  While nicotine has been demonstrated to induce cell proliferation, 
angiogenesis and growth of tumors implanted in immunodeficient mice (229), the 
studies presented here show for the first time that nicotine could indeed promote 
tumor growth in two fully immunocompetent mouse models. Further, our results 
show that the presence of nicotine can enhance the growth of lung tumors 
induced by a tobacco carcinogen.  Essentially, the A/J mouse model is reflective 
of a situation where a smoker who has tumors initiated in the lung quits smoking 
and uses nicotine supplements to overcome the craving.   Our results also show 
that a commercially available nicotine transdermal patch can promote the growth 
of tumors implanted into mice.   
 
  The finding that epithelial adhesion molecules like E-Cadherin and its 
binding partner -Catenin are affected by nicotine provides a molecular basis for 
these findings.  It can be imagined that nicotine, through the nAChR signaling 
pathways, induces changes in gene expression patterns to facilitate EMT and 
tumor metastasis. Indeed, it has been reported that the expression pattern of 
nAChR subunits are different in tumors from smokers and non-smokers (302). 
Given the ability of nicotine to affect various aspects of tumor growth and 
metastasis, it is possible that antagonists of nAChR signaling might prove 
beneficial in controlling the growth and progression of lung cancers; certain 
studies support this contention.  Further, such agents that modulate the function 
of nAChRs such as varenicline, an agonist of 42 nAChRs, might be better 
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alternatives for smoking cessation than nicotine itself.  
 
 We have shown that RRD-251 is capable of inhibiting nicotine-induced 
proliferation in line1 cells. It has previously been shown that treatment with the 
Raf-1 peptide to disrupt the Rb-Raf-1 function can inhibit nicotine induced cell 
proliferation, migration, invasion, and angiogenesis in vitro (215,297). In addition 
to targeting Rb-Raf-1, inhibition of Src activation could also prevent nicotine-
induced angiogenesis in vitro (297). Targeting the key molecules in nicotine 
mediated tumor progression and metastasis may be a better alternative for 
smokers with NSCLC. 
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Chapter 5: TNF- stimulates proliferative pathways in vascular smooth 
muscle cells 
Abstract 
 
Atherosclerosis is characterized by hyperplastic neointima and an 
inflammatory response with cytokines such as TNF-. TNF- is a pleiotropic 
cytokine that mediates inflammatory, proliferative, cytostatic, and cytotoxic 
effects in a variety of cell types, including endothelial cells (ECs) and vascular 
smooth muscle cells (VSMCs). Interestingly, TNF- has been shown to play two 
very opposing roles in these cell types; it mediates the inhibition of EC 
proliferation and induction of EC apoptosis while facilitating stimulation of 
proliferation and migration in VSMCs. Here we show that TNF- is capable of 
stimulating proliferation in rat VSMCs as well human VSMCs in a Raf-1/MAPK 
dependent manner. TNF- could increase the expression of E2F regulated 
proliferative cdc6 and cdc25A genes in AoSMCs, as seen by real time PCR 
assays. Surprisingly, we find an activation of the stress-induced kinase, JNK1, in 
VSMCs upon treatment with TNF-.  TNF- was capable of inducing the Rb-Raf-
1 interaction and treatment with the Rb-Raf-1 inhibitor, RRD-251, could prevent 
TNF- induced S-phase entry in AoSMCs. In addition, inhibition of Raf-1 or Src 
kinases using pharmacologic inhibitors could also prevent S-phase entry, while 
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inhibition of JNK was not as effective. These results suggest that inhibiting the 
Rb-Raf-1 interaction is a potential avenue to prevent VSMC proliferation 
associated with atherosclerosis.  
 
Introduction 
 
Development of atherosclerosis is a stringently regulated and complex 
process that results from aberrations in endothelial cell and vascular smooth 
muscle cell (VSMCs) function. Endothelial cells (EC) form the lining of the blood 
vessels and the heart, functioning as a barrier by regulating permeability, 
thrombogenicity, and production of growth inhibitory molecules (243). Endothelial 
cells also respond to mechanical forces. ECs are contact inhibited under normal 
conditions; but when endothelial cells sense an injury such as abrasion of a 
vessel, they proliferate and migrate leading to re-endothelialization at sites of 
injury (244). At the same time, vascular smooth muscle cells proliferate and 
migrate from the injured arterial wall into the vessel lumen leading to vessel 
thickening and occlusion, called restenosis (245). Intimal hyperplasia 
characterized by VSMC proliferation and extracellular matrix (ECM) deposition is 
a major process contributing to restenosis (246). Atherosclerotic lesions can be 
blocked if inhibition of VSMCs is effective (243).  Several growth factors and 
cytokines are capable of stimulating VSMC migration and proliferation, such as 
platelet derived growth factor (PDGF), which plays a vital role in the development 
of restenosis (247).  
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      PDGF can stimulate VSMC proliferation and migration at sites of stress 
(303). It has been shown that suppression of PDGFR activation can inhibit VSMC 
proliferation by decreasing activation of its downstream signaling molecules (304-
306). PDGF is a potent mitogen that mediates arterial response, and stimulates 
proliferation and matrix production (307). PDGF signaling leads to downstream 
activation of proliferative genes that contribute to atherosclerosis and restenosis.        
 
     Tumor necrosis factor-alpha (TNF-) is a pleiotropic inflammatory 
cytokine. Accelerated atherosclerosis is characterized by hyperplastic neointima 
and an inflammatory response with cytokines such as TNF-. TNF- has been 
shown to play two opposing roles in inhibition of endothelial cell proliferation and 
enhancement of apoptosis, while stimulating vascular smooth muscle cell 
proliferation and migration (243,308). Although there are conflicting reports on 
the ability of TNF- to stimulate VSMC proliferation, there is compelling evidence 
defining the migration stimulating activity of this cytokine (309,310). TNF-, like 
other chemoattractants such as PDGF, stimulates VSMC migration through the 
MAPK pathway (240).  
 
The apoptosis induced by TNF superfamily requires binding of a ligand to 
its receptor leading to oligotrimerization of receptors (311-313). This results in 
aggregation of death domain containing proteins allowing recruitment of TRADD 
(TNF receptor 1-associated death domain protein). TRADD binds FADD (Fas 
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associated death domain- containing protein) and TRAF-2 (TNF receptor 1-
associated protein 2) proteins, which in turn lead to activation of procaspase-8 
and apoptosis signal-regulating kinase 1 (ASK1), respectively (311,314-316). 
TNF- treatment leads to simultaneous activation of the ASK1-JNK/p38 death 
signal (315-318). Reports on the effects of TNF- on apoptosis or proliferation in 
VSMCs are conflicting (308). Several investigations report that TNF- itself does 
not induce VSMC proliferation while other studies suggest TNF- induces 
proliferation of VSMCs through NF-B mediated transcription mechanisms 
(308,319). Regarding apoptosis, there are also inconsistent reports. Certain 
studies have shown that TNF- could induce apoptosis in VSMCs via caspase-3 
activation while others found no pro-apoptotic activity for TNF- in these cells 
(309). Further investigations revealed that activity for TNF- in VSMCs is 
dependent on two distinct cell phenotypes: spindle and epithelioid VSMCs, which 
respond distinctly to diverse stimuli. While TNF- induces proliferation in spindle 
VSMCs, it induced apoptosis in epithelioid VSMCs (308).  
 
     Although PDGF and TNF- have very different signaling intermediates, 
their downstream functions require MAPK activation. It is therefore important to 
identify the upstream mechanisms contributing to increased proliferation by these 
two stimuli. Stimulation of VSMCs with PDGF leads to downstream activation of 
Erk1/2 via the Ras/Raf/MAPK (mitogen-activated protein kinase/extracellular-
signal-regulated-kinase) pathway. Activated ERK1/2 rapidly translocates to the 
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nucleus where they target transcription factors that regulate cell cycle 
progression, such as cyclin D1 (320).  Cyclin D1 binds cdk4/6 and together they 
facilitate S-phase entry through phosphorylation of the retinoblastoma (Rb) 
protein (275). Stimulation of VSMCs with TNF- has been shown to enhance 
proliferation through ERK1/2 (321) although the exact mechanism is not known. 
The Rb-Raf-1 pathway has been shown to play a role in response to mitogens as 
well as non-mitogens and enhance S-phase progression of a wide variety of cell 
lines (209,215).  Here, we show that TNF- stimulates proliferation in VSMCs by 
activating Raf-1/MEK/ERK pathway and facilitating Rb-Raf-1 interaction. 
 
Results 
 
TNF- stimulates proliferation of vascular smooth muscle cells 
  Because of conflicting reports on the effects of TNF- induced proliferation 
of VSMCs, we examined the effects of serum, TNF-, and PDGF on VSMCs by 
BrdU incorporation assays. Rat A10 cells, which are immortalized vascular 
smooth muscle cells, were serum starved for 24 hours and subsequently re-
stimulated with serum, TNF- (100ng/ml), or PDGF (100ng/ml) for 18 hours and 
S-phase entry was measured using standard BrdU incorporation assays. TNF- 
could stimulate proliferation in vascular smooth muscle cells to a certain extent 
(Figure 39A). In the same manner, we examined the effects of TNF- in primary 
human aortic vascular smooth muscle cells (AoSMCs). As shown in Figure 39B, 
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TNF- could stimulate S-phase entry comparable to PDGF; serum was used as 
the positive control.  
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Figure 39. TNF- stimulates proliferation in vascular smooth muscle cells. (A) 
Rat A10 VSMCs were serum starved and subsequently stimulated with serum, 
TNF- or PDGF for 18 hours and BrdU incorporation was measured. (B) Similar 
assay was done using human AoSMCs. 
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TNF- activates Raf/MAPK pathway in vascular smooth muscle cells 
TNF- has been shown to induce migration of vascular smooth muscle 
cells through ERK1/2 activation (240). We wanted to examine if TNF- treatment 
had any effects on Raf-1 kinase in these cells.  Treatment of vascular smooth 
muscle cells with TNF- for 10 min, 30 min, 1h and 2 hours led to a shift in Raf-1 
migration indicative of Raf-1 phosphorylation, as seen by western blotting 
(Figure 40A). Indeed, phosphorylated Raf-1 can be seen by western blotting for 
serine 338 on Raf-1; activation was highest at 1 hour of TNF- treatment (Figure 
40A). ERK1/2 activation was seen in response to TNF- and was highest at 30 
minutes of treatment (Figure 40A).  The stress activated protein kinase/ Jun-
amino terminal kinase SAPK/JNK is a member of the MAPK family that is 
potently and preferentially activated by stresses such as UV irradiation, 
ceramides and cytokines like TNF- (313). In certain instances, JNK can be 
activated by growth factors (322-324). We wanted to examine if TNF- was 
capable of activating stress kinases in a proliferative scenario. To this end, 
AoSMCs were serum starved and stimulated with TNF- or PDGF for 30 minutes 
(time point when Raf-1 activation and ERK1/2 activation was present). Western 
blotting for JNK activation using an antibody that recognizes phosphorylated 
Thr183/Tyr185 residues revealed TNF- and PDGF activated JNK in VSMCs 
(Figure 40B). Time course studies showed that activation of ERK1/2 and JNK1 
occurred at 10 minutes of stimulation and was highest at 30 minutes, activation 
went down to basal levels at 2 hours of TNF- treatment (Figure 40C).  
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Figure 40. TNF- activates Raf/MAPK pathway in VSMCs. (A) Time course 
stimulation of AoSMCs results in Raf-1 activation highest at 1 hour and ERK1/2 
activation peaks at 30 minutes. (B) Activation of ERK1/2 coincides with JNK1 
activation from 30 minutes of TNF- treatment. (C) PDGF and TNF- time 
course stimulation shows ERK1/2 and JNK activation occurs simultaneously from 
the different stimuli. 
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TNF- induced AoSMC proliferation is abrogated by targeting upstream 
activators of Raf-1 
 
   Since TNF- led to activation of Raf-1 in vascular smooth muscle cells 
and Raf-1 has been shown to play a very important role in cell proliferation we 
examined if vascular smooth muscle cell proliferation could be inhibited via 
targeting Raf-1 or kinases that activate Raf-1.  Both Src and PKC kinases are 
known to activate Raf-1 in response to growth factor signaling (175). To evaluate 
the importance of these kinases in TNF- induced proliferation, the Src inhibitor 
PP2 and the PKC inhibitor Ro-31-8220 were used in BrdU incorporation assays. 
AoSMCs were serum starved and subsequently stimulated with PDGF or TNF- 
in the presence or absence of the aforementioned inhibitors for 18 hours. BrdU 
incorporation assays revealed that both inhibition of Src and PKC could efficiently 
block TNF- or PDGF induced S-phase entry (Figure 41A). Targeting upstream 
of Raf-1 or Raf-1 itself using the multikinase inhibitor BAY-43-9006 could 
completely inhibit S-phase entry induced by PDGF or TNF- (Figure 41B). Next 
we examined if inhibition of downstream activation of JNK could prevent S-phase 
entry induced by PDGF or TNF-.  Inhibition of downstream JNK activation did 
not significantly block proliferation, suggesting that in order to efficiently block 
proliferation, activation of Raf-1 should be inhibited (Figure 41B).  
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Figure 41. Targeting Raf-1 activation blocks AoSMC proliferation. (A) Src 
inhibitor (PP2) and PKC inhibitor (Ro-31-8220) block TNF- and PDGF induced 
proliferation. (B) Multi-kinase inhibitor BAY-43-9006 that targets Raf-1 can 
completely inhibit PDGF and TNF- induced proliferation while the JNK inhibitor 
(SP600125) does not significantly affect TNF- induced proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 149 
 
TNF-α treatment induces E2F regulated genes involved in proliferation 
   Since TNF- was functioning similar to a growth factor in stimulating cell 
cycle, we examined if this was in an E2F dependent mechanism. To this end, 
Real Time PCR was performed on two E2F responsive genes from AoSMCs that 
were serum starved and subsequently stimulated with either TNF- or PDGF for 
18 hours. TNF- could induce cdc25A and cdc6 gene expression 3.5 and 3 fold 
respectively (Figure 42A-B). Next, we examined if in fact E2F1 was present on 
the proliferative promoter cdc25A in response to TNF-.  Treatment with TNF- 
or PDGF for 18 hours led to an increase in E2F1 on the cdc25A promoter and a 
dissociation of Rb (Figure 42C).  In quiescent cells, we consistently observed a 
faint band for E2F1 on the cdc25A promoter and the presence of Rb was also 
detected in starved cells on this promoter. The c-fos promoter was used as a 
negative control.  
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Figure 42. TNF- and PDGF induce E2F regulated genes in AoSMCs. (A) 
Treatment with TNF- and PDGF for 18 hours led to 3.5 and 4 fold increase, 
respectively in cdc25A gene expression in real time PCR assays. (B) Treatment 
with TNF- and PDGF for 18 hours led to 3.5 and 7 fold increase, respectively in 
cdc6 gene expression in real time PCR assays. (C) Treatment with TNF- or 
PDGF led to an increase in E2F1 and dissociation of Rb on the proliferative 
promoter cdc25A in ChIP assays, c-fos was used as the negative control. 
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TNF- induced AoSMC proliferation involves Rb-Raf-1 interaction 
 
   Our lab has shown the importance of the Rb-Raf-1 interaction in mediating 
proliferation in a wide array of cell lines. Since Raf-1 activation is evident in 
response to TNF- induced proliferation in AoSMCs, we examined if Raf-1-Rb 
interaction is involved in mediating these effects. Treatment with the Rb-Raf-1 
inhibitor RRD-251 in the presence of TNF- or PDGF for 2 hours could efficiently 
reduce Raf-1 levels in both AoSMCs and rat A10 cells (Figure 43A-B). Next, we 
examined if TNF- stimulation of AoSMCs could induce the Rb-Raf-1 interaction, 
this was done by IP-WB analysis.  Treatment with TNF- and PDGF for 2 hours 
led to an increase in Raf-1 bound to Rb; in addition there was less E2F1 
associated in the TNF- and PDGF stimulated complexes (Figure 43C). We next 
examined if RRD-251 could prevent serum, TNF- or PDGF induced proliferation 
in AoSMCs. AoSMCs were serum starved and subsequently stimulated with 
serum, TNF-, or PDGF in the presence or absence of 20M RRD-251. In 
response to all three stimuli, RRD-251 was capable of inhibiting S-phase entry in 
AoSMCs (Figure 43D). These results suggest that inhibiting Rb-Raf-1 interaction 
and signaling might be a viable alternative to prevent atherosclerosis.  
 
 
 
 
 
 152 
 
Figure 43.  Inhibition of Rb-Raf-1 interaction prevents AoSMC proliferation. (A-B) 
treatment with TNF- or PDGF in the presence of RRD-251 inhibits Raf-1 levels 
in AoSMCs (A) and A10s (B). (C) TNF- and PDGF treatment induced Rb-Raf-1 
binding in AoSMCs. (D) Treatment with RRD-251 inhibits AoSMC proliferation 
induced by serum, TNF- and PDGF. 
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Discussion 
 
   The dynamics of endothelial and vascular smooth muscle cells play the 
predominant role in the progression of atherosclerosis and restenosis.  Migration, 
proliferation, and differentiation of ECs as well as VSMCs are important 
pathological responses that contribute to the development of vascular lesions. 
The „switch‟ of VSMCs from the quiescent phenotype to the proliferative and 
migratory phenotype is a vital event in the pathogenesis of atherosclerosis and 
restenosis post-angioplasty. Therefore, VSMC proliferation and migration both 
serve as suitable targets for drug therapy in vascular proliferative disorders. This 
study provides evidence that TNF- and PDGF evoke similar signaling 
mechanisms that contribute to VSMC proliferation. Although they are not equally 
efficacious in activating these pathways, TNF- is capable of activating growth 
factor receptor signaling pathways. S-phase entry assays revealed that TNF- is 
capable of stimulating cell cycle progression in vascular smooth muscle cells. 
The proliferative response also increased E2F regulated genes cdc6 and 
cdc25A, in fact TNF- stimulation led to an increase in E2F1 on the proliferative 
promoter cdc25A. One interesting finding was in response to TNF-, Raf/MAPK 
activation occurred and this coincided with an activation of the stress kinase 
JNK1. Inhibition of TNF- or PDGF induced cell proliferation with pharmacologic 
inhibitors targeting Raf-1, upstream of Raf-1 or JNK displayed inhibition of S-
phase entry only when targeting Src, PKC or Raf-1 not JNK. This suggests that 
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JNK activation most likely is not responsible for the proliferative responses seen 
with TNF-.   
Studies from our lab have shown that upon TNF- treatment, ASK1 is 
responsible for Rb inactivation as an initial signaling event in Ramos and Jurkat 
cells (237). We observe similar response in HAECs where Rb is inactivated on 
TNF- treatment in addition to upregulation of the pro-apoptotic proteins like p73 
(unpublished data). The role of p53 in TNF- induced apoptosis has been 
controversial (325,326). We also find that TNF- has no affect on p53 expression 
however p73 levels were found to be upregulated implicating p73 to be major 
contributing factor to endothelial apoptosis induced by TNF-. We have observed 
that TNF- signaling in ECs functions in an E2F1 regulated apoptotic pathway 
(unpublished data). Especially in this context the studies from our lab show that 
Rb interacts with ASK1 upon apoptotic stimuli, and ASK1 has to overcome Rb 
function to execute its pro-apoptotic functions suggesting that Rb acts as a 
critical connector between apoptotic and proliferative pathways, by interacting 
with the functionally distinct kinases like Raf-1 and ASK1 (237). Thus the role of 
Rb phosphorylation by specific kinases is pertinent for directed signaling for 
apoptotic or proliferative pathways (234). 
  
The contrasting observation in AoSMCs, where TNF- treatment resulted 
in a lack of apoptotic response and increase in proliferation suggests that TNF is 
involved in multiple pathways depending on the cellular context. We observed 
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activation of Raf-1 and ERK, which are also indicative of a proliferative response. 
It has been shown that a colocalization of TNF- and ERK1/2 occurs and ERK 
1/2 activation induces the expression of Ets-1, Egr-1, and c-fos in neointimal 
lesions from rat aortae 2 weeks post balloon injury (327). The ChIP and RT-PCR 
experiments showed recruitment of E2F1 to proliferative promoters suggesting 
that E2F1 is a key mediator in the TNF- induced proliferative or apoptotic 
pathways in VSMCs or ECs, respectively.  
 
   Rb-Raf-1 interaction was found to play a vital role for serum, PDGF and 
TNF- induced proliferation in VSMCs. Targeting Rb-Raf-1 interaction using 
RRD-251 could completely inhibit S-phase entry in these cells. Our lab has 
previously shown that disrupting the Rb-Raf-1 interaction can prevent endothelial 
cell adhesion, migration and proliferation. Taken together, the importance of this 
interaction in both endothelial cell as well as vascular smooth muscle cell 
physiology in atherosclerotic lesions needs further evaluation and may provide 
useful tools in development of therapies for heart disease. This study is an 
attempt to delineate mechanisms underlying the differential effects of E2F-1 in 
different cellular activities with regard to the involvement of proliferative and 
apoptotic genes. The divergent responses of AoSMCs and HAECs to TNF- thus 
provide unique therapeutic possibilities: simultaneously targeting the cell cycle of 
two different cell types, within same tissue microenvironment resulting in 
opposite and biologically complimentary effects.  
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 Summary and Conclusions 
 
   Rb plays a vital role in cell proliferation and its inactivation facilitates S-
phase entry (257). It has been well accepted that inactivation of Rb occurs 
through a cascade of phosphorylation events mediated by kinases associated 
with D and E type cyclins (328). Rb is known to have growth suppressive 
properties and an inhibition of Rb phosphorylation can lead to a G1 arrest (329). 
Several studies have suggested that mitogenic signaling pathways converge on 
the Rb dependent g1/S checkpoint (330,331). Members of the Ras/Raf/MAPK 
pathway have been shown to be involved in the upregulation of cyclinD1 and Rb 
phosphorylation (171,330,331).  Furthermore, it has been shown that Ras 
mediated transformation and stimulated cell cycle progression requires inhibition 
of Rb activation through cyclin D (332). It is well established that most cancers 
inactivate Rb function by regulating the phosphorylation events that govern its 
function.  Studies from our laboratory have shown that Raf-1 is capable of 
binding to Rb and facilitating its inactivation and this occurs prior to the binding of 
cyclins and cdks (173,209). We find that the Rb-Raf-1 interaction facilitates 
mitogenic and non-mitogenic stimulation and disruption of this interaction has 
great therapeutic potential for controlling proliferative disorders.  
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   Although it has been difficult to generate small molecule protein-protein 
interactions that translate to the clinic the recent successes in disrupting the 
hdm-2-p53 protein-protein interaction clearly show that this is a viable strategy 
for developing novel drugs (269,279). We have described the discovery and 
characteristics of a novel protein-protein inhibitor for the disruption of the Rb-Raf-
1. We have shown that blocking the Rb-Raf-1 interaction can prevent S-phase 
entry in a wide range of cancer cell lines including lung, breast, prostate, brain, 
pancreatic, and melanoma; indicating that the Rb-Raf-1 interaction may be 
involved in mediating cell cycle progression is several cancers of varying origin. 
RRD-251 also prevented tumor growth in vivo in both lung and melanoma 
xenografts. 
 
   Our lab has specifically focused on the Rb-Raf-1 interaction in NSCLC, 
mainly because nicotine and tobacco carcinogens such as NNK have been 
shown to stimulate the binding of Raf-1 to Rb in normal lung cells as well a lung 
cancer cells (215).  In addition, non-small cell lung cancer (NSCLC) is associated 
with 80% of the total number of lung cancer cases and is strongly associated with 
tobacco use. Our lab and others have shown that the Rb-Raf-1 interaction is 
found to be elevated in human NSCLC tissue samples compared to adjacent 
control suggesting that this pathway contributes to the oncogenesis of these 
tumors (215). Blocking the Rb-Raf-1 interaction with either the Raf-1 peptide or 
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RRD-251 could prevent nicotine induced proliferation and angiogenesis in vitro 
(297).  Future in vivo experiments could reveal whether blocking the Rb-Raf-1 
interaction is necessary to prevent nicotine induced lung metastasis. These 
studies along with other in vivo models will open the door to developing novel 
therapeutic for treatment of NSCLC in smokers. 
   In another scenario, we find the Rb-Raf-1 interaction to mediate both 
endothelial cell and vascular smooth muscle cell proliferation. In endothelial cells, 
mitogenic as well as nicotine stimulation induced the Rb-Raf-1 interaction and 
cell proliferation. In vascular smooth muscle cells, mitogenic as well as non-
mitogenic (cytokine-TNF-) stimulation induced the Rb-Raf-1 interaction and cell 
proliferation. ECs and VSMCs in the heart respond to a variety of stimuli that 
decides if and when these cells will either proliferate or die (apoptosis). The 
proliferative response of these cells contributes to vessel thickening (occlusion) 
often known as restenosis or atherosclerosis. Inhibition of the Rb-Raf-1 
interaction with RRD-251 prevented both EC and VSMC proliferation.  
   Based on the above findings we propose that inhibition of Rb-Raf-1 
interaction is a viable mechanism for the treatment of proliferative disorders. We 
have shown that treatment with the Rb-Raf-1 disruptor RRD-251 could prevent 
cell cycle progression in response to a wide range of cell signals. In addition, 
smokers may have elevated levels of Rb-Raf-1 interaction and disrupting this 
interaction may help prevent the progression of NSCLC.  
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